John Q. Trojanowski

John Q. Trojanowski's AcademicInfluence.com Rankings

John Q. Trojanowski

Biology

#823

World Rank

#1429

Historical Rank

#439

USA Rank

Biochemistry

#76

World Rank

#96

Historical Rank

#48

USA Rank

biology Degrees

John Q. Trojanowski

Philosophy

#1288

World Rank

#2378

Historical Rank

#523

USA Rank

Logic

#166

World Rank

#390

Historical Rank

#74

USA Rank

philosophy Degrees

Download Badge

Biology
Philosophy

John Q. Trojanowski's Degrees

Doctorate Medicine University of Pennsylvania
PhD Biochemistry University of Pennsylvania

Why Is John Q. Trojanowski Influential?

(Suggest an Edit or Addition)

According to Wikipedia, John Quinn Trojanowski was an American academic research neuroscientist specializing in neurodegeneration. He and his partner, Virginia Man-Yee Lee, MBA, Ph.D., are noted for identifying the roles of three proteins in neurodegenerative diseases: tau in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and TDP-43 in Amyotrophic Lateral Sclerosis and frontotemporal degeneration.

(See a Problem?)

John Q. Trojanowski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis (2006) (5319)
α-Synuclein in Lewy bodies (1997) (4852)
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade (2010) (3896)
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 (1998) (3363)
Diagnosis and management of dementia with Lewy bodies (2005) (3346)
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers (2013) (3207)
The Alzheimer's disease neuroimaging initiative. (2005) (3069)
Alpha-synuclein in Lewy bodies. (1997) (2847)
Second consensus statement on the diagnosis of multiple system atrophy (2008) (2532)
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (2012) (2093)
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects (2009) (1922)
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders (2007) (1898)
Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice (2012) (1886)
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2011) (1839)
Neurodegenerative tauopathies. (2001) (1834)
Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease (2011) (1656)
Diagnosis and management of dementia with Lewy bodies (2017) (1606)
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. (2000) (1546)
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature (2012) (1494)
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. (1998) (1493)
Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease (1997) (1458)
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. (2001) (1424)
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model (2007) (1409)
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. (1991) (1399)
Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. (2012) (1388)
Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death (2011) (1200)
The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. (2001) (1129)
Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease (2001) (1113)
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease (1997) (1105)
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS (2010) (1095)
Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS (2013) (1085)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
Alzheimer's Disease Neuroimaging Initiative (2008) (1024)
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study (2012) (1007)
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration (2007) (1007)
Primary age-related tauopathy (PART): a common pathology associated with human aging (2014) (988)
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein (2002) (974)
Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2005) (970)
Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. (1998) (951)
Harnessing neuroplasticity for clinical applications (2011) (894)
Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations (2007) (887)
Synucleins Are Developmentally Expressed, and α-Synuclein Regulates the Size of the Presynaptic Vesicular Pool in Primary Hippocampal Neurons (2000) (882)
A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* (2001) (882)
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice (2012) (871)
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update (2009) (869)
Molecular basis of phenotypic variability in sporadc creudeldt‐jakob disease (1996) (843)
Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3 (1997) (822)
Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways (2015) (816)
Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding (1993) (810)
Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein (2003) (802)
Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells (2009) (793)
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. (2013) (786)
A harmonized classification system for FTLD-TDP pathology (2011) (781)
Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS (2011) (763)
Stages of pTDP‐43 pathology in amyotrophic lateral sclerosis (2013) (747)
Alzheimer's Disease Neuroimaging Initiative (ADNI) (2010) (712)
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis (2008) (701)
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs (2004) (688)
Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls (2013) (671)
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report (2019) (646)
Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein (1998) (625)
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies (2013) (609)
Spreading of pathology in neurodegenerative diseases: a focus on human studies (2015) (599)
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers (2008) (579)
The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging (1999) (578)
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. (2002) (577)
Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. (2013) (572)
Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform (1999) (571)
Comparing predictors of conversion and decline in mild cognitive impairment (2010) (570)
Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons (2013) (567)
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. (2002) (559)
Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration (2011) (557)
Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease (2000) (557)
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau (1994) (555)
The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception (2012) (553)
Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS (2010) (548)
Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. (1995) (543)
The acetylation of tau inhibits its function and promotes pathological tau aggregation. (2011) (543)
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification (2011) (540)
Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro * (1999) (534)
Experimental Brain Injury Induces Regionally Distinct Apoptosis during the Acute and Delayed Post-Traumatic Period (1998) (532)
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. (2002) (530)
Disturbance of Nuclear and Cytoplasmic TAR DNA-binding Protein (TDP-43) Induces Disease-like Redistribution, Sequestration, and Aggregate Formation* (2008) (527)
Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy (2013) (525)
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception (2012) (513)
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. (1998) (497)
Gene expression changes in the course of normal brain aging are sexually dimorphic (2008) (486)
Epitopes that span the tau molecule are shared with paired helical filaments (1988) (485)
Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. (1998) (478)
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans (2010) (473)
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease (2010) (464)
Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease (2012) (461)
Frontotemporal dementia: Clinicopathological correlations (2006) (456)
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies (2009) (448)
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. (2010) (446)
Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery (2006) (444)
Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. (2004) (443)
Synucleinopathies: clinical and pathological implications. (2001) (443)
Relationships between biomarkers in aging and dementia (2009) (440)
Progressive atrophy and neuron death for one year following brain trauma in the rat. (1997) (437)
The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. (1993) (437)
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. (2007) (436)
Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years (2008) (435)
Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis (2016) (424)
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. (1999) (417)
Genetic evidence for the involvement of τ in progressive supranuclear palsy (1997) (417)
Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. (1999) (415)
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene (2018) (414)
Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo (1998) (414)
Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. (1996) (409)
Neuropathologic substrates of Parkinson disease dementia (2012) (406)
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies (2009) (404)
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations (2008) (398)
Brain MR: pathologic correlation with gross and histopathology. 1. Lacunar infarction and Virchow-Robin spaces. (1988) (398)
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans (2010) (395)
Amyotrophic lateral sclerosis—a model of corticofugal axonal spread (2013) (395)
Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration (2008) (392)
TAR DNA-binding protein 43 in neurodegenerative disease (2010) (390)
At the interface of sensory and motor dysfunctions and Alzheimer's disease (2015) (389)
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance (2012) (388)
Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. (2006) (385)
The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
MRI and CSF biomarkers in normal, MCI, and AD subjects (2009) (384)
CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts (2018) (380)
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. (2005) (379)
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases (2007) (378)
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury (2004) (378)
Astrocyte Senescence as a Component of Alzheimer’s Disease (2012) (378)
Enduring cognitive, neurobehavioral and histopathological changes persist for up to one year following severe experimental brain injury in rats (1998) (377)
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation (2019) (372)
Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline (2010) (371)
Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity (2000) (369)
Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult (2001) (369)
Axonal transport defects: a common theme in neurodegenerative diseases (2005) (366)
Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation (2017) (363)
Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies (2018) (361)
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? (2003) (359)
Transplantation of Cryopreserved Human Embryonal Carcinoma-Derived Neurons (NT2N Cells) Promotes Functional Recovery in Ischemic Rats (1998) (359)
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. (2013) (357)
DLB and PDD boundary issues (2007) (351)
Clinicopathological correlations in corticobasal degeneration (2011) (351)
Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* (2002) (347)
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein (2000) (346)
Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. (2011) (345)
Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans (2007) (344)
Repetitive Mild Brain Trauma Accelerates Aβ Deposition, Lipid Peroxidation, and Cognitive Impairment in a Transgenic Mouse Model of Alzheimer Amyloidosis (2002) (344)
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. (2013) (342)
Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy (2015) (340)
Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy (2003) (339)
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated (2018) (338)
Plasma tau in Alzheimer disease (2016) (337)
Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies (2008) (337)
Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau (*) (1995) (334)
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease (2013) (332)
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis (2017) (329)
The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice (2012) (329)
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease (2010) (328)
Expression profile of transcripts in Alzheimer's disease tangle‐bearing CA1 neurons (2000) (328)
A yeast functional screen predicts new candidate ALS disease genes (2011) (327)
Current state of Alzheimer’s fluid biomarkers (2018) (327)
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. (2016) (326)
Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies* (2009) (322)
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics (2007) (321)
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases (2002) (318)
Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. (1995) (316)
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease (2010) (314)
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects (2010) (311)
Therapeutic modulation of eIF2α-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models (2013) (310)
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. (2006) (309)
Neurofilaments and Orthograde Transport Are Reduced in Ventral Root Axons of Transgenic Mice that Express Human SOD1 with a G93A Mutation (1997) (308)
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis (2012) (308)
Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease (2004) (305)
Brain MR: pathologic correlation with gross and histopathology. 2. Hyperintense white-matter foci in the elderly. (1988) (304)
Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis (2010) (304)
Mild head injury increasing the brain's vulnerability to a second concussive impact. (2001) (303)
Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer's disease (1995) (300)
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid (2013) (300)
Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias (2014) (295)
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome (2018) (288)
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. (2008) (287)
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception (2015) (287)
Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease (2016) (287)
PP2A mRNA Expression Is Quantitatively Decreased in Alzheimer's Disease Hippocampus (2001) (285)
Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies (2002) (283)
APOE ε4 increases risk for dementia in pure synucleinopathies. (2013) (282)
Metabolic network failures in Alzheimer's disease: A biochemical road map (2017) (280)
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI (2011) (275)
Unique pathological tau conformers from Alzheimer’s brains transmit tau pathology in nontransgenic mice (2016) (275)
Neuropathology of synuclein aggregates (2000) (274)
Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease (2011) (274)
Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia (1998) (274)
Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. (1998) (272)
α-Synuclein Immunotherapy Blocks Uptake and Templated Propagation of Misfolded α-Synuclein and Neurodegeneration (2014) (272)
Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration (2005) (271)
Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. (2008) (269)
Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. (2009) (269)
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD (2011) (269)
Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration (2015) (266)
Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. (2002) (265)
The future of blood-based biomarkers for Alzheimer's disease (2014) (265)
Distinct MRI Atrophy Patterns in Autopsy-Proven Alzheimer's Disease and Frontotemporal Lobar Degeneration (2008) (265)
Frontotemporal dementia progresses to death faster than Alzheimer disease (2005) (265)
The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. (2002) (265)
The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury. (1999) (265)
Accumulation of amyloid beta and tau and the formation of neurofilament inclusions following diffuse brain injury in the pig. (1999) (265)
Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. (2003) (264)
Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy (2010) (264)
Frontotemporal dementia and its subtypes: a genome-wide association study (2014) (262)
Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* (2005) (261)
Biological markers for therapeutic trials in Alzheimer’s disease Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease (2003) (261)
Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. (2000) (257)
Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy (2007) (257)
Typical and atypical pathology in primary progressive aphasia variants (2017) (257)
Prion-like domain mutations in hnRNPs cause multisystem proteinopathy and ALS (2013) (253)
Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice (2002) (252)
Antibodies to α‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease (1999) (252)
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. (1996) (250)
Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. (2012) (250)
TDP-43 Mediates Degeneration in a Novel Drosophila Model of Disease Caused by Mutations in VCP/p97 (2010) (248)
Mutations in COQ2 in familial and sporadic multiple-system atrophy. (2013) (246)
TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. (2016) (246)
Concurrence of α-synuclein and tau brain pathology in the Contursi kindred (2002) (243)
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. (2015) (243)
Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease (2002) (242)
Biochemical and pathological characterization of Lrrk2 (2006) (239)
Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain (2017) (235)
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts (2007) (234)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. (2012) (233)
Clinical and pathological continuum of multisystem TDP-43 proteinopathies. (2009) (232)
Gene expression profile for schizophrenia: discrete neuron transcription patterns in the entorhinal cortex. (2002) (232)
The cells of origin of the corpus callosum in rat, cat and rhesus monkey. (1974) (232)
Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides. (1993) (231)
CSF biomarkers in frontotemporal lobar degeneration with known pathology (2008) (230)
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration (2010) (230)
Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. (1991) (229)
Altered Tau and Neurofilament Proteins in Neuro‐Degenerative Diseases: Diagnostic Implications for Alzheimer's Disease and Lewy Body Dementias (1993) (226)
TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. (2000) (226)
Protein transmission in neurodegenerative disease (2020) (226)
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative (2018) (225)
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. (2012) (225)
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease (2005) (225)
Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) (2014) (222)
Long-Term Accumulation of Amyloid-β, β-Secretase, Presenilin-1, and Caspase-3 in Damaged Axons Following Brain Trauma (2004) (221)
Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases (1995) (220)
Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model (2001) (219)
Evidence for ordering of Alzheimer disease biomarkers. (2011) (217)
Recent advances in defining the neuropathology of schizophrenia (1996) (216)
Expression and analysis of presenilin 1 in a human neuronal system: localization in cell bodies and dendrites. (1996) (216)
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. (2002) (216)
Glucocerebrosidase mutations are an important risk factor for Lewy body disorders (2006) (214)
Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials (2017) (214)
Tau isoform profile and phosphorylation state in dementia pugilistica recapitulate Alzheimer's disease (2001) (213)
A panel of epitope‐specific antibodies detects protein domains distributed throughout human α‐synuclein in lewy bodies of Parkinson's disease (2000) (212)
Human fetal hippocampal development: I. Cytoarchitecture, myeloarchitecture, and neuronal morphologic features (1996) (212)
Expression of neurofilament subunits in neurons of the central and peripheral nervous system: an immunohistochemical study with monoclonal antibodies (1986) (211)
12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. (2004) (211)
Induction of alpha-synuclein aggregation by intracellular nitrative insult. (2001) (211)
Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. (2015) (211)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
TDP-43-Positive White Matter Pathology in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions (2007) (209)
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. (2012) (208)
Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies (2000) (207)
A Lack of Amyloid β Plaques Despite Persistent Accumulation of Amyloid β in Axons of Long‐Term Survivors of Traumatic Brain Injury (2009) (207)
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement (2017) (206)
TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease (2007) (205)
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research (2015) (205)
Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. (2015) (204)
Phosphorylated α-Synuclein in Parkinson’s Disease (2012) (203)
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease (2012) (202)
An R5L τ mutation in a subject with a progressive supranuclear palsy phenotype (2002) (202)
Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine (2015) (201)
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. (2000) (200)
Expression of GDNF mRNA in Rat and Human Nervous Tissue (1994) (200)
Chronic Stress Exacerbates Tau Pathology, Neurodegeneration, and Cognitive Performance through a Corticotropin-Releasing Factor Receptor-Dependent Mechanism in a Transgenic Mouse Model of Tauopathy (2011) (200)
Nitration of tau protein is linked to neurodegeneration in tauopathies. (2003) (197)
Microglial Activation Correlates with Disease Progression and Upper Motor Neuron Clinical Symptoms in Amyotrophic Lateral Sclerosis (2012) (197)
Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. (2001) (196)
Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer’s disease or corticobasal degeneration brains (2015) (196)
Areal and laminar distribution of some pulvinar cortical efferents in rhesus monkey (1976) (196)
Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis (2017) (196)
Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary (2000) (195)
Impact Acceleration Injury in the Rat: Evidence for Focal Axolemmal Change and Related Neurofilament Sidearm Alteration (1997) (195)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2019) (194)
Clinicopathological correlations in behavioural variant frontotemporal dementia (2017) (193)
Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. (1998) (193)
IMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques (2002) (193)
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. (2002) (191)
Cognitive and motor assessment in autopsy-proven corticobasal degeneration (2007) (191)
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model (2007) (190)
Altered expression of bcl‐2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons (1996) (190)
An acetylation switch controls TDP-43 function and aggregation propensity (2015) (190)
Dementia resulting from dural arteriovenous fistulas: the pathologic findings of venous hypertensive encephalopathy. (1998) (190)
Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy (2004) (189)
Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. (2012) (189)
Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice* (2006) (188)
TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord (2014) (187)
Tau pathology in a family with dementia and a P301L mutation in tau. (1999) (187)
Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion (2012) (186)
TDP-43 pathology, cognitive decline, and dementia in old age. (2013) (186)
Amyotrophic lateral sclerosis, frontotemporal dementia and beyond: the TDP-43 diseases (2009) (183)
Transplanted human neurons derived from a teratocarcinoma cell line (NTera‐2) mature, integrate, and survive for over 1 year in the nude mouse brain (1995) (182)
A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. (2010) (182)
Embryonic neuronal markers in tuberous sclerosis: single-cell molecular pathology. (1996) (182)
TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. (2011) (182)
TMEM106B, the Risk Gene for Frontotemporal Dementia, Is Regulated by the microRNA-132/212 Cluster and Affects Progranulin Pathways (2012) (182)
Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. (2003) (181)
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. (2008) (181)
MRI and CSF biomarkers in normal, MCI, and AD subjects (2009) (181)
Autosomal dominant dementia with widespread neurofibrillary tangles (1997) (180)
TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. (2007) (180)
‘Unfolding’ pathways in neurodegenerative disease (2003) (179)
Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy (2018) (179)
More than just two peas in a pod: common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases (2004) (178)
Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau (2009) (177)
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. (2020) (177)
Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med (1985) (177)
“Fatal Attractions” of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders (2000) (176)
Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI (2011) (175)
Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort (2010) (175)
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 (2015) (175)
APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. (2014) (175)
Prefrontal granular cortex of the rhesus monkey. I. Intrahemispheric cortical afferents (1977) (174)
Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. (2001) (174)
Alzheimer's Disease Neuroimaging Initiative: A one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition (2009) (173)
Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43 (2015) (173)
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. (2010) (173)
Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. (2016) (172)
Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: A spectrum of TDP‐43 proteinopathies (2010) (172)
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases (2012) (171)
Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease (2018) (171)
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI (2013) (170)
BACE1 activity is modulated by cell-associated sphingosine-1-phosphate (2011) (170)
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease (2009) (169)
Olfactory epithelium amyloid‐β and paired helical filament‐tau pathology in Alzheimer disease (2010) (169)
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study (2016) (169)
Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. (2001) (169)
Longitudinal change of biomarkers in cognitive decline. (2011) (169)
Longitudinal study of normal cognition in Parkinson disease (2015) (168)
Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment (2010) (168)
Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. (1991) (168)
The cytoskeleton in neurodegenerative diseases (2004) (167)
Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer's disease. (2008) (167)
Pathological TDP-43 in parkinsonism–dementia complex and amyotrophic lateral sclerosis of Guam (2007) (167)
Prefrontal granular cortex of the rhesus monkey. II. Interhemispheric cortical afferents (1977) (167)
Distinct cerebral perfusion patterns in FTLD and AD (2010) (166)
Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC’s afferent and efferent connections (2015) (164)
Alterations in metabolic pathways and networks in Alzheimer's disease (2013) (164)
Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies (2008) (164)
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. (2011) (164)
Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease (2004) (163)
Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study (2018) (163)
Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies (2017) (162)
Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice (2015) (162)
Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. (2013) (162)
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (2001) (161)
Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury (2004) (160)
Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. (1996) (159)
Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease (2001) (159)
Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia (1996) (159)
Transgenic Mouse Model of Tau Pathology in Astrocytes Leading to Nervous System Degeneration (2005) (158)
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. (2008) (158)
Alpha-synuclein-induced aggregation of cytoplasmic vesicles in Saccharomyces cerevisiae. (2007) (157)
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease (2009) (157)
Biological markers of amyloid β-related mechanisms in Alzheimer's disease (2010) (157)
GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease (2016) (157)
Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy (2015) (157)
Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. (1997) (156)
Redox signalling directly regulates TDP‐43 via cysteine oxidation and disulphide cross‐linking (2012) (156)
Cholera toxin and wheat germ agglutinin conjugates as neuroanatomical probes: Their uptake and clearance, transganglionic and retrograde transport and sensitivity (1982) (156)
TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia (2010) (155)
Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis (2013) (155)
Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age* (2003) (155)
Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. (2011) (153)
A distinct familial presenile dementia with a novel missense mutation in the tau gene. (1999) (153)
Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. (2012) (153)
Altered Neuronal Mitochondrial Coenzyme A Synthesis in Neurodegeneration with Brain Iron Accumulation Caused by Abnormal Processing, Stability, and Catalytic Activity of Mutant Pantothenate Kinase 2 (2005) (151)
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers (2018) (151)
Serial MRI and CSF biomarkers in normal aging, MCI, and AD (2010) (151)
Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer’s disease (2019) (150)
Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease (2004) (150)
Sporadic Pick's disease: A tauopathy characterized by a spectrum of pathological τ isoforms in gray and white matter (2002) (149)
Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. (2004) (148)
A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank (2014) (148)
Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer’s disease and tauopathies (2014) (148)
TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss (2017) (148)
Conjugates of horseradish peroxidase (HRP) with cholera toxin and wheat germ agglutinin are superior to free HRP as orthogradely transported markers (1981) (148)
The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases. (1994) (147)
Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro (1985) (147)
Clinical and multimodal biomarker correlates of ADNI neuropathological findings (2013) (147)
Horseradish peroxidase (HRP) conjugates of cholera toxin and lectins are more sensitive retrogradely transported markers than free HRP (1982) (146)
Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques. (1990) (146)
Distribution patterns of tau pathology in progressive supranuclear palsy (2020) (146)
β-Synuclein gene alterations in dementia with Lewy bodies (2004) (145)
Neurons and neuroendocrine cells contain chromogranin: detection of the molecule in normal bovine tissues by immunochemical and immunohistochemical methods. (1985) (145)
Protein accumulation in traumatic brain injury (2007) (145)
Characterizing Alzheimer's disease using a hypometabolic convergence index (2011) (145)
Sequestration of RNA in Alzheimer's disease neurofibrillary tangles and senile plaques (1997) (144)
Selective Destruction of Stable Microtubules and Axons by Inhibitors of Protein Serine/Threonine Phosphatases in Cultured Human Neurons (NT2N Cells) (1997) (144)
Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology (2010) (144)
DJ‐1 colocalizes with tau inclusions: A link between parkinsonism and dementia (2004) (144)
Parkinson's Disease and Related α‐Synucleinopathies Are Brain Amyloidoses (2003) (144)
Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease (2011) (144)
The Neuropathology of a Chromosome 17-Linked Autosomal Dominant Parkinsonism and Dementia (“Pallido-Ponto-Nigral Degeneration”) (1998) (143)
The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease (2013) (143)
Immunohistochemical and Biochemical Studies Demonstrate a Distinct Profile of α‐Synuclein Permutations in Multiple System Atrophy (2000) (142)
Transgenic animal models of tauopathies. (2005) (142)
The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies. (2011) (141)
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology (2019) (141)
Modulation of Nuclear Factor-κB Activity by Indomethacin Influences Aβ Levels but Not Aβ Precursor Protein Metabolism in a Model of Alzheimer's Disease (2004) (140)
Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis (2012) (140)
Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration (2002) (140)
Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. (1998) (140)
Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. (2006) (140)
Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. (2014) (140)
Fibrillization of α-synuclein and tau in familial Parkinson's disease caused by the A53T α-synuclein mutation (2004) (138)
P301S Mutant Human Tau Transgenic Mice Manifest Early Symptoms of Human Tauopathies with Dementia and Altered Sensorimotor Gating (2011) (138)
Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. (1988) (138)
APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern (2015) (138)
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI) (2013) (137)
Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. (2002) (137)
Tau and axonopathy in neurodegenerative disorders (2002) (137)
Heterogeneity of neuroanatomical patterns in prodromal Alzheimer’s disease: links to cognition, progression and biomarkers (2016) (136)
Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers. (2013) (136)
Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term (2017) (135)
BACE overexpression alters the subcellular processing of APP and inhibits Aβ deposition in vivo (2005) (135)
Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. (2000) (135)
α‐synuclein is developmentally expressed in cultured rat brain oligodendrocytes (2000) (135)
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology (2012) (135)
Distinct cleavage patterns of normal and pathologic forms of α‐synuclein by calpain I in vitro (2003) (134)
Modeling Parkinson’s disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain (2017) (134)
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative (2020) (133)
Postmortem analysis of adrenal–medulla–to–caudate autograft in a patient with parkinson's disease (1989) (133)
Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. (1995) (133)
Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model. (2005) (132)
Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo (2018) (132)
In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. (2000) (132)
Vascular disease and dementias: Paradigm shifts to drive research in new directions (2013) (131)
Signature tau neuropathology in gray and white matter of corticobasal degeneration. (2002) (131)
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease (2015) (131)
Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders (2019) (130)
TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading (2018) (130)
Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. (2014) (130)
Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration (2017) (130)
Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review (2019) (129)
Ubiquitination of α-Synuclein Is Not Required for Formation of Pathological Inclusions in α-Synucleinopathies (2003) (128)
Extensive FUS‐Immunoreactive Pathology in Juvenile Amyotrophic Lateral Sclerosis with Basophilic Inclusions (2010) (128)
Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy body disorders (1996) (128)
Predominance of neuronal mRNAs in individual Alzheimer's disease senile plaques (1999) (126)
Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. (2012) (126)
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects (2010) (126)
Lewy body pathology in Alzheimer’s disease (2001) (126)
Interactions between Hsp70 and the hydrophobic core of alpha-synuclein inhibit fibril assembly. (2008) (124)
Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous α-Synuclein Inclusions of α-Synucleinopathies (2006) (124)
Therapeutic strategies for tau mediated neurodegeneration (2012) (124)
Deep clinical and neuropathological phenotyping of Pick disease (2016) (124)
α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies (2019) (124)
“New Old Pathologies”: AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS) (2016) (123)
In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-β and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders (2011) (123)
Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. (2016) (123)
Neurons Derived from a Human Teratocarcinoma Cell Line Establish Molecular and Structural Polarity Following Transplantation into the Rodent Brain (1993) (122)
Alzheimer disease tangles share immunological similarities with multiphosphorylation repeats in the two large neurofilament proteins. (1988) (122)
Inflammatory hypotheses: novel mechanisms of Alzheimer’s neurodegeneration and new therapeutic targets? (2000) (121)
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker (2013) (121)
TDP-43 Proteinopathies: Neurodegenerative Protein Misfolding Diseases without Amyloidosis (2007) (120)
The Expression of α-, β-, and γ-Synucleins in Olfactory Mucosa from Patients with and without Neurodegenerative Diseases (1999) (120)
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions (2014) (119)
Expression patterns of β‐amyloid precursor protein (β‐APP) in neural and nonneural human tissues from alzheimer's disease and control subjects (1991) (119)
Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models (2015) (118)
Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins). (1992) (118)
Corticothalamic neurons and thalamocortical terminal fields: An investigation in rat using horseradish peroxidase and autoradiography (1975) (118)
Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology. (2004) (118)
Pesticide Exposure Exacerbates α-Synucleinopathy in an A53T Transgenic Mouse Model (2007) (118)
alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. (2004) (118)
Nerve Growth Factor Induces Apoptosis in Human Medulloblastoma Cell Lines that Express TrkA Receptors (1997) (118)
dorsolateral prefrontal cortex (1999) (117)
Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers (2017) (117)
Dysregulation of olfactory receptor neuron lineage in schizophrenia. (2001) (116)
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition (2011) (116)
RNA sequestration to pathological lesions of neurodegenerative diseases (1998) (116)
An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer’s disease (2020) (115)
Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment (2005) (115)
Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. (2016) (115)
Aminothienopyridazines and Methylene Blue Affect Tau Fibrillization via Cysteine Oxidation* (2013) (115)
Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. (2008) (115)
Human olfactory epithelium in normal aging, alzheimer's disease, and other neurodegenerative disorders (1991) (115)
Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers☆☆☆ (2013) (115)
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls (2009) (114)
Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. (2004) (114)
Characterizing the human hippocampus in aging and Alzheimer’s disease using a computational atlas derived from ex vivo MRI and histology (2018) (114)
Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. (2008) (113)
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort (2018) (113)
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. (2011) (113)
Prospective clinicopathologic studies of schizophrenia: accrual and assessment of patients. (1995) (113)
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. (2013) (112)
Glial fibrillary acidic protein-immunoreactive astrocytosis in elderly patients with schizophrenia and dementia (1996) (112)
Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology (2016) (112)
Mild traumatic brain injury induces apoptotic cell death in the cortex that is preceded by decreases in cellular Bcl-2 immunoreactivity (2002) (112)
α-Synuclein pathology spread through the brain connectome is modulated by selective vulnerability and predicted by network analysis (2019) (111)
Plasma apolipoprotein A1 as a biomarker for Parkinson disease (2013) (111)
Intraneuronal APP, Not Free Aβ Peptides in 3xTg-AD Mice: Implications for Tau versus Aβ-Mediated Alzheimer Neurodegeneration (2011) (110)
A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114 (2003) (110)
An immunohistochemical study of human central and peripheral nervous system tumors, using monoclonal antibodies against neurofilaments and glial filaments. (1984) (110)
TDP-43: a novel neurodegenerative proteinopathy (2007) (109)
Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases (2017) (109)
Oxidation of Cytosolic Proteins and Expression of Creatine Kinase BB in Frontal Lobe in Different Neurodegenerative Disorders (1999) (109)
Update on hypothetical model of Alzheimer's disease biomarkers (2013) (109)
Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes (2006) (109)
Novel monoclonal antibodies provide evidence for the in situ existence of a nonphosphorylated form of the largest neurofilament subunit (1986) (108)
Age-dependent synuclein pathology following traumatic brain injury in mice (2003) (108)
Epitopes located in spatially separate domains of each neurofilament subunit are present in parkinson's disease lewy bodies (1991) (107)
Native and derivatized lectins for in vivo studies of neuronal connectivity and neuronal cell biology (1983) (107)
Genetic correlation between amyotrophic lateral sclerosis and schizophrenia (2017) (107)
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. (2001) (107)
Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies (2005) (107)
RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy‐Related Pathology in the Dementia Patient (2008) (107)
Paired helical filament tau in Alzheimer's disease. The kinase connection. (1994) (107)
Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers (2019) (106)
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. (2015) (106)
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology (2018) (106)
Primitive Neuroectodermal Tumors of the Central Nervous System (1997) (106)
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease (2017) (105)
Degradative organelles containing mislocalized α- and β-synuclein proliferate in presenilin-1 null neurons (2004) (105)
IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain. (2001) (104)
Chronic traumatic encephalopathy — confusion and controversies (2019) (104)
Selectively Silencing GSK-3 Isoforms Reduces Plaques and Tangles in Mouse Models of Alzheimer's Disease (2012) (104)
A mutation affecting the sodium/proton exchanger, SLC9A6, causes mental retardation with tau deposition. (2010) (104)
Tau and α-Synuclein Pathology in Amygdala of Parkinsonism-Dementia Complex Patients of Guam (2002) (104)
Expression of trk receptors in the developing and adult human central and peripheral nervous system (1995) (104)
Transfectable and Transplantable Postmitotic Human Neurons: A Potential “Platform” for Gene Therapy of Nervous System Diseases (1997) (103)
Molecular milestones that signal axonal maturation and the commitment of human spinal cord precursor cells to the neuronal or glial phenotype in development (1991) (103)
Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative (2012) (103)
Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia (2010) (103)
A “Two-hit” Hypothesis for Inclusion Formation by Carboxyl-terminal Fragments of TDP-43 Protein Linked to RNA Depletion and Impaired Microtubule-dependent Transport* (2011) (103)
Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis (2011) (102)
Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. (2012) (101)
Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study (2010) (101)
Axonal Degeneration Induced by Targeted Expression of Mutant Human Tau in Oligodendrocytes of Transgenic Mice That Model Glial Tauopathies (2005) (101)
Nosology of Parkinson’s Disease: Looking for the Way Out of a Quackmire (2005) (101)
Non-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study (2018) (101)
α-Syn Suppression Reverses Synaptic and Memory Defects in a Mouse Model of Dementia with Lewy Bodies (2011) (100)
A90V TDP‐43 variant results in the aberrant localization of TDP‐43 in vitro (2008) (100)
Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis (2011) (100)
Cytoarchitecture of the extranuclear and commissural dendrites of hypoglossal nucleus neurons as revealed by conjugates of horseradish peroxidase with cholera toxin (1982) (99)
Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. (2006) (99)
Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein (1999) (99)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture (2021) (99)
Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. (2012) (98)
Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. (2004) (98)
Acetylated tau neuropathology in sporadic and hereditary tauopathies. (2013) (98)
Cleavage of α-Synuclein by Calpain: Potential Role in Degradation of Fibrillized and Nitrated Species of α-Synuclein† (2005) (98)
Rapid and Intermittent Cotransport of Slow Component-b Proteins (2007) (98)
Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis (2019) (98)
Neurodegenerative Tauopathies Human Disease and Transgenic Mouse Models (1999) (98)
Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation (2000) (98)
Variants associated with Gaucher disease in multiple system atrophy (2015) (97)
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. (2011) (97)
Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP (2013) (97)
Brain Microvascular Pericytes in Vascular Cognitive Impairment and Dementia (2020) (97)
Phosphorylated alpha-Synuclein in Parkinson's Disease (2012) (96)
Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. (2014) (96)
Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. (2009) (96)
Improvement of cognitive deficits and decreased cholinergic neuronal cell loss and apoptotic cell death following neurotrophin infusion after experimental traumatic brain injury (1997) (95)
CSF biomarker and PIB-PET–derived beta-amyloid signature predicts metabolic, grey matter and cognitive changes in nondemented subjects (2011) (95)
Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. (2010) (95)
Interactions of amyloidogenic proteins (2007) (95)
Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. (2005) (94)
TDP-43 skeins show properties of amyloid in a subset of ALS cases (2012) (94)
Novel CSF biomarkers for frontotemporal lobar degenerations (2010) (94)
Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. (2007) (94)
High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. (2007) (94)
Overexpression of the human NFM subunit in transgenic mice modifies the level of endogenous NFL and the phosphorylation state of NFH subunits (1995) (93)
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease (2014) (93)
Axon pathology in Parkinson ’ s disease and Lewy body dementia hippocampus contains a-, b-, and g-synuclein (1999) (93)
Medial pulvinar afferents to frontal eye fields in rhesus monkey demonstrated by horseradish peroxidase. (1974) (93)
In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease (2000) (93)
Cerebral ischemia and CNS transplantation: differential effects of grafted fetal rat striatal cells and human neurons derived from a clonal cell line (1998) (93)
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid (2011) (92)
Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors (2010) (92)
Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease. (2014) (91)
Single-Cell Gene Expression Analysis: Implications for Neurodegenerative and Neuropsychiatric Disorders (2004) (91)
Amyloid β-Protein (Aβ) 1–40 But Not Aβ1–42 Contributes to the Experimental Formation of Alzheimer Disease Amyloid Fibrils in Rat Brain (1997) (91)
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition (2014) (91)
Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology (2019) (91)
High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease Tauopathies (2020) (91)
Localization of the mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and senile plaque neurites (1993) (90)
Neuron‐specific age‐related decreases in dopamine receptor subtype mRNAs (2003) (90)
Physical activity and cognitive health (2007) (90)
Genetically Modified NT2N Human Neuronal Cells Mediate Long‐Term Gene Expression as CNS Grafts In Vivo and Improve Functional Cognitive Outcome Following Experimental Traumatic Brain Injury (2003) (90)
Brain Trauma in Aged Transgenic Mice Induces Regression of Established Aβ Deposits (2000) (90)
Biomarkers for Early Detection of Alzheimer Pathology (2007) (90)
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. (2015) (89)
PolyQ Repeat Expansions in ATXN2 Associated with ALS Are CAA Interrupted Repeats (2011) (89)
CSF α-synuclein improves diagnostic and prognostic performance of CSF tau and Aβ in Alzheimer’s disease (2013) (89)
Survival profiles of patients with frontotemporal dementia and motor neuron disease. (2009) (89)
Twofold overexpression of human β‐amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury (1998) (89)
Beta-synuclein gene alterations in dementia with Lewy bodies. (2004) (88)
Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells (2000) (88)
Human fetal hippocampal development: II. The neuronal cytoskeleton (1996) (88)
Amygdaloid projections to prefrontal granular cortex in rhesus monkey demonstrated with horseradish peroxidase (1975) (87)
Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment (2012) (87)
Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease (2007) (87)
Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease (1994) (86)
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. (2020) (86)
Glial differentiation predicts poor clinical outcome in primitive neuroectodermal brain tumors (1996) (85)
Quantification of Modified Amyloid β Peptides in Alzheimer Disease and Down Syndrome Brains (1998) (85)
Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent rats. (1999) (85)
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls (2017) (85)
Pathological tau: a loss of normal function or a gain in toxicity? (2005) (85)
Internexin, MAP1B, and nestin in cortical dysplasia as markers of developmental maturity (1997) (85)
Clinical marker for Alzheimer disease pathology in logopenic primary progressive aphasia (2017) (84)
Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease (1995) (84)
Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. (2012) (84)
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays (2019) (84)
Update on the Neuropathological Diagnosis of Frontotemporal Dementias (2001) (84)
Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases (2017) (84)
Differential Expression and Distribution of α-, β-, and γ-Synuclein in the Developing Human Substantia Nigra (2001) (84)
Conversion between Mini‐Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale‐2 scores in Parkinson's disease (2014) (83)
Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis (2004) (83)
Long‐term integration and neuronal differentiation of human embryonal carcinoma cells (NT era‐2) transplanted into the caudoputamen of nude mice (1996) (83)
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study (2018) (83)
White matter imaging helps dissociate tau from TDP-43 in frontotemporal lobar degeneration (2013) (82)
Neocortical and hippocampal amyloid-β and tau measures associate with dementia in the oldest-old. (2011) (82)
Effects of α-tocopherol on an animal model of tauopathies (2004) (81)
17q-linked frontotemporal dementia-amyotrophic lateral sclerosis without tau mutations with tau and alpha-synuclein inclusions. (2004) (81)
Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease (2010) (81)
Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation (2019) (81)
Induction of neurofilament triplet proteins in PC12 cells by nerve growth factor (1982) (81)
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. (2018) (81)
Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia (2003) (81)
Acute and chronically increased immunoreactivity to phosphorylation-independent but not pathological TDP-43 after a single traumatic brain injury in humans (2011) (80)
Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer’s Disease and Related Tauopathies (2014) (80)
Ex vivo gene therapy using targeted engraftment of NGF-expressing human NT2N neurons attenuates cognitive deficits following traumatic brain injury in mice. (2004) (80)
The North American Multiple System Atrophy Study Group (2005) (80)
τ Phosphorylation in Human, Primate, and Rat Brain: Evidence that a Pool of τ Is Highly Phosphorylated In Vivo and Is Rapidly Dephosphorylated In Vitro (1994) (80)
Quantitative neurohistological features of frontotemporal degeneration (2000) (79)
A combined horseradish peroxidase-autoradiographic investigation of reciprocal connections between superior temporal gyrus and pulvinar in squirrel monkey (1975) (79)
Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players (2019) (79)
Microtubule stabilizing drugs for the treatment of Alzheimer's disease (1994) (79)
Phenotypic Analysis of Four Human Medulloblastoma Cell Lines and Transplantable Xenografts (1989) (79)
Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology (2018) (78)
Expression of neuronal and glial polypeptides during histogenesis of the human cerebellar cortex including observations on the dentate nucleus (1993) (78)
Tau Proteins Are Abnormally Expressed in Olfactory Epithelium of Alzheimer Patients and Developmentally Regulated in Human Fetal Spinal Cord (1993) (78)
D2-40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas (2005) (78)
A review and rationale for the use of cellular transplantation as a therapeutic strategy for traumatic brain injury. (2004) (78)
Pathobiology of the Lewy body. (1999) (78)
Proteasome Inhibition Stabilizes Tau Inclusions in Oligodendroglial Cells that Occur after Treatment with Okadaic Acid (2003) (78)
Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration (2016) (77)
Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment (2000) (77)
Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments (2001) (77)
Longitudinal decline in autopsy-defined frontotemporal lobar degeneration (2008) (77)
A comparison of eight different chromogen protocols for the demonstration of immunoreactive neurofilaments or glial filaments in rat cerebellum using the peroxidase-antiperoxidase method and monoclonal antibodies. (1983) (77)
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges (2016) (77)
Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. (2004) (77)
-synuclein modulates -synuclein neurotoxicity by reducing -synuclein protein expression (2006) (76)
Subicular dendritic arborization in Alzheimer's disease correlates with neurofibrillary tangle density. (2003) (76)
Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells (2004) (76)
Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. (2003) (76)
Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. (2014) (76)
The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. (2001) (76)
Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease (2019) (76)
Impaired rapid eye movement sleep in the Tg2576 APP murine model of Alzheimer's disease with injury to pedunculopontine cholinergic neurons. (2005) (75)
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. (2003) (75)
Altered microtubule dynamics in neurodegenerative disease: Therapeutic potential of microtubule-stabilizing drugs (2017) (75)
Transmission of tauopathy strains is independent of their isoform composition (2019) (75)
Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. (2005) (74)
People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance (2014) (74)
Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons (1993) (74)
Amyloid plaques in cerebellar cortex and the integrity of Purkinje cell dendrites (1994) (74)
Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology (2013) (74)
Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
Reduction of Detyrosinated Microtubules and Golgi Fragmentation Are Linked to Tau-Induced Degeneration in Astrocytes (2003) (73)
Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. (2007) (73)
Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease (2016) (73)
The disordered neuronal cytoskeleton in Alzheimer's disease (1992) (72)
Neuronal origin of human esthesioneuroblastoma demonstrated with anti-neurofilament monoclonal antibodies. (1982) (72)
The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans (2015) (72)
Sex and APOE ε4 genotype modify the Alzheimer’s disease serum metabolome (2020) (71)
Transactive response DNA-binding protein 43 burden in familial Alzheimer disease and Down syndrome. (2009) (71)
The neuropathology of dementia (2004) (71)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
Long-term deep brain stimulation in a patient with essential tremor: clinical response and postmortem correlation with stimulator termination sites in ventral thalamus. Case report. (2000) (70)
Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. (2010) (70)
Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons (2016) (70)
Cellular and Molecular Neuropathology of the Olfactory Epithelium and Central Olfactory Pathways in Alzheimer's Disease and Schizophrenia a (1998) (69)
Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. (2019) (69)
Neurofibrillary Tangles in Progressive Supranuclear Palsy Contain the Same Tau Epitopes Identified in Alzheimer's Disease PHFtau (1996) (69)
Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72‐associated amyotrophic lateral sclerosis (2017) (69)
T1ρ MRI of Alzheimer's disease (2008) (69)
Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders (2018) (69)
TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system (2008) (69)
Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis (2016) (68)
In vivo measurement of plaque burden in a mouse model of Alzheimer's disease (2006) (68)
Brain progranulin expression in GRN-associated frontotemporal lobar degeneration (2009) (68)
Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis (2018) (68)
Transmission of α-synuclein seeds in neurodegenerative disease: recent developments (2019) (68)
Interneuronal transfer of axonally transported proteins: studies with HRP and HRP conjugates of wheat germ agglutinin, cholera toxin and the B subunit of cholera toxin (1984) (67)
Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. (2002) (67)
Exercise and cognition: Results from the National Long Term Care Survey (2010) (67)
Characterization of unmyelinated axons uniting epidermal and dermal immune cells in primate and murine skin (1998) (67)
Relative abundance of tau and neurofilament epitopes in hippocampal neurofibrillary tangles. (1990) (66)
Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairments (2005) (66)
Immunohistochemical application of monoclonal antibodies against myelin basic protein and neurofilament triple protein subunits: advantages over antisera and technical limitations. (1983) (66)
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease (2019) (66)
Neurodegenerative dementias : clinical features and pathological mechanisms (2000) (65)
Distribution of neurofilament subunits in neurons and neuronal processes: immunohistochemical studies of bovine cerebellum with subunit-specific monoclonal antibodies. (1985) (65)
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult (2019) (65)
The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. (1999) (65)
Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration (2015) (65)
Monoclonal antibodies to a synthetic peptide homologous with the first 28 amino acids of Alzheimer's disease beta-protein recognize amyloid and diverse glial and neuronal cell types in the central nervous system. (1989) (65)
A frontal variant of Alzheimer’s disease exhibits decreased calcium-independent phospholipase A2 activity in the prefrontal cortex (2000) (64)
Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease. (2015) (64)
Peroxidase labeled subcortical afferents to pulvinar in rhesus monkey (1975) (64)
Selective Degeneration of Purkinje Cells with Lewy Body-Like Inclusions in Aged NFHLACZ Transgenic Mice (1997) (63)
CSF Apo-E levels associate with cognitive decline and MRI changes (2014) (63)
Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD (2019) (63)
Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease (2013) (63)
Astrocytic TDP-43 Pathology in Alexander Disease (2014) (63)
Association of ABCA2 expression with determinants of Alzheimer's disease (2004) (63)
Building an integrated neurodegenerative disease database at an academic health center (2011) (63)
Biochemical Analysis of τ Proteins in Argyrophilic Grain Disease, Alzheimer's Disease, and Pick's Disease: A Comparative Study (2002) (63)
Emerging β-amyloid pathology and accelerated cortical atrophy. (2014) (63)
A detailed immunohistochemical analysis of cerebellar hemangioblastoma: an undifferentiated mesenchymal tumor. (1989) (62)
Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease. (2012) (62)
The role of tau in Alzheimer's disease. (2002) (62)
Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. (1990) (62)
Characterization of tau fibrillization in vitro (2010) (62)
Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain (2018) (62)
Molecular features of hypothalamic plaques in Alzheimer's disease. (1991) (62)
Protein astrogliopathies in human neurodegenerative diseases and aging (2017) (62)
An English kindred with a novel recessive tauopathy and respiratory failure (2003) (62)
Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease (2006) (61)
Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia complex patients of Guam. (2002) (61)
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease (2019) (61)
Cerebrospinal fluid tau, Aβ, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration (2018) (60)
Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions (1994) (60)
Identification of phosphorylation sites in PHF-TAU from patients with Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex. (1996) (60)
Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. (2004) (60)
Olfactory dysfunction occurs in transgenic mice overexpressing human τ protein (2004) (60)
Early marker for Alzheimer's disease: Hippocampus T1rho (T1ρ) estimation (2009) (60)
The disordered neuronal cytoskeleton in Alzheimer's disease (1992) (60)
Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease (2017) (60)
The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. (1990) (60)
Apolipoprotein E gene in Parkinson's disease with or without dementia (1994) (60)
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders (2018) (59)
Introduction of nerve growth factor (NGF) receptors into a medulloblastoma cell line results in expression of high- and low-affinity NGF receptors but not NGF-mediated differentiation. (1990) (59)
Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease (2012) (59)
Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease (1994) (59)
CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline (2018) (59)
Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline (2010) (59)
Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit (2012) (58)
Early fetal acquisition of the chromaffin and neuronal immunophenotype by human adrenal medullary cells. An immunohistological study using monoclonal antibodies to chromogranin A, synaptophysin, tyrosine hydroxylase, and neuronal cytoskeletal proteins (1990) (58)
A Novel Apoptotic Pathway Induced by Nerve Growth Factor-mediated TrkA Activation in Medulloblastoma* (2000) (58)
Neural differentiation of rhesus embryonic stem cells (1998) (58)
TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. (2007) (58)
Cell-to-Cell Transmission of Tau and α-Synuclein. (2020) (58)
Cerebellar Dysplasias in Humans: Development and Possible Relationship to Glial and Primitive Neuroectodermal Tumors of the Cerebellar Vermis (1994) (58)
Neurotrophin and neurotrophin receptor proteins in medulloblastomas and other primitive neuroectodermal tumors of the pediatric central nervous system. (1996) (58)
CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders (2013) (57)
Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. (2007) (57)
Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net (2011) (57)
Amyotrophic lateral sclerosis-plus syndrome with TAR DNA-binding protein-43 pathology. (2009) (57)
Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases (2013) (57)
Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease (1998) (57)
Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline (2010) (57)
Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease (1998) (57)
Traumatic brain injury in young, amyloid‐β peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Aβ deposition during aging (1999) (57)
Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. (2006) (56)
TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling (2017) (56)
Terminally differentiated human neurons survive and integrate following transplantation into the traumatically injured rat brain. (1999) (56)
Distribution of phosphate-independent MAP2 epitopes revealed with monoclonal antibodies in microwave-denatured human nervous system tissues (1989) (56)
The power of neuroimaging biomarkers for screening frontotemporal dementia (2014) (56)
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium (2020) (56)
Cortical biochemistry in MCI and Alzheimer disease (2007) (56)
Human tau pathology transmits glial tau aggregates in the absence of neuronal tau (2019) (55)
The TMEM106B locus and TDP-43 pathology in older persons without FTLD (2015) (55)
Cognitive profile of LRRK2‐related Parkinson's disease (2015) (55)
Patterns of MRI atrophy in tau positive and ubiquitin positive frontotemporal lobar degeneration (2007) (55)
Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer’s Disease Neuroimaging Initiative study patients (2012) (55)
Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer’s disease in veterans, using the Alzheimer’s Disease Neuroimaging Initiative (2014) (55)
Purification of paired helical filament tau and normal tau from human brain tissue. (1999) (55)
Genome-wide, high-content siRNA screening identifies the Alzheimer’s genetic risk factor FERMT2 as a major modulator of APP metabolism (2016) (55)
Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer’s disease, and Parkinson’s disease (2018) (55)
Alzheimer's disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. (2003) (54)
Spinal Cord Neurofibrillary Pathology in Alzheimer Disease and Guam Parkinsonism‐Dementia Complex (2001) (54)
Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer’s Disease (2020) (54)
Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis (2005) (54)
Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel (2013) (54)
Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. (2014) (54)
Monoclonal antibodies to purified cortical lewy bodies recognize the mid‐size neurofilament subunit (1997) (54)
Phosphorylation of Neuronal Cytoskeletal Proteins in Alzheimer's Disease and Lewy Body Dementias a (1994) (54)
Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. (2017) (53)
Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease (2013) (53)
Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. (1995) (53)
Tauists, Baptists, Syners, Apostates, and new data (2002) (53)
Detection of Alzheimer Disease (AD)-Specific Tau Pathology in AD and NonAD Tauopathies by Immunohistochemistry With Novel Conformation-Selective Tau Antibodies (2018) (53)
α-Synuclein (αSyn) Preformed Fibrils Induce Endogenous αSyn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons (2019) (53)
Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration (2022) (53)
Plasma biomarkers of depressive symptoms in older adults (2012) (53)
Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration (2007) (53)
T1rho (T1ρ) MR imaging in Alzheimer’ disease and Parkinson’s disease with and without dementia (2011) (52)
Higher CSF sTREM2 and microglia activation are associated with slower rates of beta‐amyloid accumulation (2020) (52)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study (2021) (52)
Selective reduction of soluble Tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study (2003) (52)
Cytoskeletal Requirements in Axonal Transport of Slow Component-b (2008) (52)
Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging (2016) (52)
The older rabbit as an animal model: Implications for Alzheimer's disease (1996) (51)
In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology (2014) (51)
On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia (2011) (51)
Patterns of Striatal Degeneration in Frontotemporal Dementia (2013) (51)
Improvement of cognitive deficits and decreased cholinergic neuronal cell loss and apoptotic cell death following neurotrophin infusion after experimental traumatic brain injury. (1997) (51)
Impact of TREM2 risk variants on brain region-specific immune activation and plaque microenvironment in Alzheimer’s disease patient brain samples (2019) (51)
Animal Models of Medulloblastomas and Related Primitive Neuroectodermal Tumors. A Review (1995) (51)
α-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases (2004) (51)
Sex differences in the genetic predictors of Alzheimer's pathology. (2019) (51)
A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes (2018) (51)
Motor neuron disease clinically limited to the lower motor neuron is a diffuse TDP-43 proteinopathy (2011) (50)
An extensive network of PHFτ‐rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease (1994) (50)
Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy (2016) (50)
Increased Vulnerability of NFH-LacZ Transgenic Mouse to Traumatic Brain Injury-Induced Behavioral Deficits and Cortical Damage (1999) (50)
Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. (2000) (50)
The Impact of Exercise, Cognitive Activities, and Socialization on Cognitive Function (2014) (49)
Polymorphisms of dopamine receptor and transporter genes and Parkinson's disease (1995) (49)
A68 is a component of paired helical filaments of Gerstmann-Sträussler-Scheinker disease, Indiana kindred (1993) (49)
Medulloblastomas and related primitive neuroectodermal brain tumors of childhood recapitulate molecular milestones in the maturation of neuroblasts. (1992) (49)
Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration (2014) (48)
Therapy of a Murine Model of Pediatric Brain Tumors using a Herpes Simplex Virus Type‐1 ICP34.5 Mutant and Demonstration of Viral Replication within the CNS (1996) (48)
Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses (2007) (48)
PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease (2015) (48)
Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. (1999) (47)
Analysis of tau haplotypes in Pick’s disease (2002) (47)
Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U (2013) (47)
Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation. (2010) (47)
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease (2012) (47)
Delayed transplantation of human neurons following brain injury in rats: a long-term graft survival and behavior study. (2005) (47)
Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors. (2007) (47)
Prominent Perikaryal Expression of α- and β-Synuclein in Neurons of Dorsal Root Ganglion and in Medullary Neurons (2001) (47)
Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible (2002) (47)
Does chondroid chordoma exist? (2004) (47)
A Review and Rationale for the Use of Genetically Engineered Animals in the Study of Traumatic Brain Injury (2001) (47)
Malignant pineocytoma with prominent papillary features (1982) (47)
Expression of α-, β-, and γ-synuclein in glial tumors and medulloblastomas (2003) (47)
Accumulation of Intracellular Amyloid-β Peptide (Aβ 1–40) in Mucopolysaccharidosis Brains (1999) (47)
A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system. (1998) (46)
Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus (2012) (46)
A light and electron microscopic study of the intraneuronal transport of horseradish peroxidase and wheat germ agglutinin-peroxidase conjugates in the rat visual system (1981) (46)
A quantitative correlation of substance P-, calcitonin gene-related peptide- and cholecystokinin-like immunoreactivity with retrogradely labeled trigeminal ganglion cells innervating the eye (1987) (46)
Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging (2013) (46)
Vertical gaze ophthalmoplegia (1980) (46)
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 (2010) (45)
Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease (2018) (45)
Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease (1992) (45)
Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease : a comparative study. (2002) (45)
Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults (2014) (45)
Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease (2018) (45)
Isomerization of (Z,Z) to (E,E)1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene in strong base: probes for amyloid plaques in the brain. (2001) (45)
The development and convergence of co-pathologies in Alzheimer's disease. (2020) (45)
Lewy bodies contain beta-amyloid precursor proteins of Alzheimer's disease (1992) (45)
β-Amyloid Peptide and Amyloid Precursor Proteins in Olfactory Mucosa of Patients with Alzheimer's Disease, Parkinson's Disease, and down Syndrome (1995) (45)
FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expression (2009) (45)
Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer’s Disease and Related Tauopathies (2016) (44)
Cognitive and functional resilience despite molecular evidence of Alzheimer’s disease pathology (2013) (44)
The transcriptional activation domain of VP16 is required for efficient infection and establishment of latency by HSV-1 in the murine peripheral and central nervous systems. (1999) (44)
Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration (2017) (44)
Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy (2016) (44)
The transitional association between β-amyloid pathology and regional brain atrophy (2014) (44)
Clinicopathological Study of Patients With C9ORF72-Associated Frontotemporal Dementia Presenting With Delusions (2015) (43)
Factors associated with survival probability in autopsy-proven frontotemporal lobar degeneration (2007) (43)
Progression of alpha‐synuclein pathology in multiple system atrophy of the cerebellar type (2017) (43)
A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits. (1987) (43)
Building a roadmap for developing combination therapies for Alzheimer’s disease (2015) (43)
Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. (2012) (43)
Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein. (1999) (43)
Phosphate-dependent and independent neurofilament protein epitopes are expressed throughout the cell cycle in human medulloblastoma (D283 MED) cells. (1989) (43)
Asymmetry of post-mortem neuropathology in behavioural-variant frontotemporal dementia. (2018) (43)
Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals (2014) (42)
New insights into genetic and molecular mechanisms of brain degeneration in tauopathies (2000) (42)
Novel conformation‐selective alpha‐synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease (2017) (42)
Differential effects of spinal cord gray and white matter on process outgrowth from grafted human NTERA2 neurons (NT2N, hNT) (1999) (42)
Expression of alpha-, beta-, and gamma-synuclein in glial tumors and medulloblastomas. (2003) (42)
Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. (2006) (42)
Development, validation and application of a new fornix template for studies of aging and preclinical Alzheimer's disease (2016) (42)
Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines. (1993) (42)
Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex: Transgenic Mice Provide Insights into Mechanisms Underlying a Common Tauopathy in an Ethnic Minority on Guam (2002) (42)
Neurofilament reassembly in vitro: biochemical, morphological and immuno-electron microscopic studies employing monoclonal antibodies to defined epitopes (1991) (41)
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques (2021) (41)
Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium (2019) (41)
Bilateral subthalamic nucleus deep brain stimulation for advanced PD: Correlation of intraoperative MER and postoperative MRI with neuropathological findings (2003) (41)
Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations (2008) (41)
An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice. (2015) (41)
Alzheimer disease A68 proteins injected into rat brain induce codeposits of beta-amyloid, ubiquitin, and alpha 1-antichymotrypsin. (1993) (41)
Genetic variation in the brain derived neurotrophic factor gene in Alzheimer's disease (2005) (41)
Crossed aphasia in a dextral (1980) (41)
Unexpected abundance of pathological tau in progressive supranuclear palsy white matter (2006) (41)
Amyloid beta-protein (Abeta) 1-40 but not Abeta1-42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. (1997) (40)
Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis (2020) (40)
Relationship between Plasma Analytes and SPARE-AD Defined Brain Atrophy Patterns in ADNI (2013) (40)
High-throughput quantitative histological analysis of Alzheimer's disease pathology using a confocal digital microscanner (1999) (40)
Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. (2015) (40)
Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases (2020) (40)
Behavioral Variant Frontotemporal Dementia with Corticobasal Degeneration Pathology: Phenotypic Comparison to bvFTD with Pick’s Disease (2011) (40)
ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease (2014) (40)
Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies. (2011) (40)
Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention (2011) (40)
Cognitive impairment in elderly schizophrenia: a dementia (still) lacking distinctive histopathology. (1996) (40)
Sex-specific genetic predictors of Alzheimer’s disease biomarkers (2018) (40)
Monoclonal and polyclonal antibodies against neural antigens: diagnostic applications for studies of central and peripheral nervous system tumors. (1983) (39)
Nerve growth factor receptor expression in peripheral and central neuroectodermal tumors, other pediatric brain tumors, and during development of the adrenal gland. (1991) (39)
TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia (2019) (39)
Iodinated tracers for imaging amyloid plaques in the brain. (2003) (39)
Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures (2015) (39)
Effects of alpha-tocopherol on an animal model of tauopathies. (2004) (39)
Primum non nocere: a call for balance when reporting on CTE (2019) (39)
Apolipoprotein E genotype in schizophrenia: frequency, age of onset, and neuropathologic features (1997) (39)
Neurobiology of human neurons (NT2N) grafted into mouse spinal cord: implications for improving therapy of spinal cord injury. (2000) (39)
The Molecular and Genetic Basis of Neurological Disease (1993) (39)
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. (2015) (39)
Expression of neurofilament and neuron‐specific enolase in small cell tumors of skin using immunohistochemistry (1985) (39)
The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. (2016) (39)
Tau immunophenotypes in chronic traumatic encephalopathy recapitulate those of ageing and Alzheimer's disease. (2020) (39)
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study (2020) (38)
Expression patterns of beta-amyloid precursor protein (beta-APP) in neural and nonneural human tissues from Alzheimer's disease and control subjects. (1991) (38)
C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy (2019) (38)
Serial MRI and CSF biomarkers in normal aging, MCI and Alzheimer's disease (2010) (38)
Transcriptomic Changes Due to Cytoplasmic TDP-43 Expression Reveal Dysregulation of Histone Transcripts and Nuclear Chromatin (2015) (38)
Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α-Syn) Pathology in Synthetic α-Syn Fibril-Induced Mouse Models of Synucleinopathy. (2019) (38)
Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice. (2009) (38)
Neurofibrillary pathology and aluminum in Alzheimer's disease. (1995) (38)
Association of plasma and cortical amyloid beta is modulated by APOE ε4 status (2014) (38)
Molecular Pathology of Alzheimer’s Disease and Related Disorders (1999) (38)
Strategies for Improving the Postmortem Neuropathological Diagnosis of Alzheimer’s Disease (1997) (38)
Lowering the risk of Alzheimer’s disease: Evidence-based practices emerge from new research (2005) (38)
Biomarkers in frontotemporal lobar degenerations—Progress and challenges (2011) (38)
“Emerging Alzheimer’s disease therapies: focusing on the future” (2002) (38)
Tau Pathology Drives Dementia Risk-Associated Gene Networks toward Chronic Inflammatory States and Immunosuppression (2020) (37)
Measurements of auto‐antibodies to α‐synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease (2018) (37)
Neurotrophins and neuronal versus glial differentiation in medulloblastomas and other pediatric brain tumors (1998) (37)
APOE, thought disorder, and SPARE‐AD predict cognitive decline in established Parkinson's disease (2018) (37)
Semi-Automated Digital Image Analysis of Pick’s Disease and TDP-43 Proteinopathy (2016) (37)
Transgenic Models of Tauopathies and Synucleinopathies (1999) (37)
Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study (2015) (36)
Differential expression and distribution of alpha-, beta-, and gamma-synuclein in the developing human substantia nigra. (2001) (36)
Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions (2012) (36)
α-Synuclein modulates tau spreading in mouse brains (2020) (36)
Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease (2018) (36)
Tau and 14-3-3 in glial cytoplasmic inclusions of multiple system atrophy (2003) (36)
Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease (2020) (36)
Alzheimers disease biomarkers: from concept to clinical utility (2008) (36)
Amyloid plaques in Guam amyotrophic lateral sclerosis/ parkinsonism-dementia complex contain species of Aβ similar to those found in the amyloid plaques of Alzheimer’s disease and pathological aging (1998) (36)
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease (2020) (36)
Synphilin in normal human brains and in synucleinopathies: studies with new antibodies (2003) (35)
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications. (2013) (35)
Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. (2020) (35)
Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype (2015) (35)
Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. (2011) (35)
A novel modification of the avidin-biotin complex method for immunohistochemical studies of transgenic mice with murine monoclonal antibodies. (1992) (34)
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies (2015) (34)
Expression of Neurofilament Proteins in the Hypertrophic Granule Cells of Lhermitte-Duclos Disease: An Explanation for the Mass Effect and the Myelination of Parallel Fibers in the Disease State (1988) (34)
Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease (1998) (34)
Selective Vulnerability of Mouse CNS Neurons to Latent Infection with a Neuroattenuated Herpes Simplex Virus-1 (1996) (34)
Endoscopic human olfactory biopsy technique: A preliminary report (1993) (34)
A morphometric study of the endocytosis of wheat germ agglutinin-horseradish peroxidase conjugates by retinal ganglion cells in the rat (1983) (34)
Monoclonal antibodies to a 100-kd protein reveal abundant A beta-negative plaques throughout gray matter of Alzheimer's disease brains. (1997) (34)
Detection of amyloid plaques by radioligands for Aβ40 and Aβ42 (2003) (33)
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease (2016) (33)
CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease? (2014) (33)
Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. (1998) (33)
Caregiver report of apathy predicts dementia in Parkinson's disease. (2015) (33)
Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties. (2012) (33)
Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases (2017) (33)
Expression of neurofilament antigens by normal and neoplastic human adrenal chromaffin cells. (1985) (32)
Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG) (2017) (32)
An Alzheimer’s Disease-Derived Biomarker Signature Identifies Parkinson’s Disease Patients with Dementia (2016) (32)
The Sigma-2 Receptor/TMEM97, PGRMC1, and LDL Receptor Complex Are Responsible for the Cellular Uptake of Aβ42 and Its Protein Aggregates (2020) (32)
Asymmetric bilateral demyelinating optic neuropathy from tacrolimus toxicity (2011) (32)
Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain. (2001) (32)
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease (2021) (32)
Rotenone Neurotoxicity: A New Window on Environmental Causes of Parkinson's Disease and Related Brain Amyloidoses (2003) (32)
Divergent patterns of TDP‐43 and tau pathologies in primary progressive aphasia (2019) (32)
LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice (2019) (32)
Forebrain overexpression of α-synuclein leads to early postnatal hippocampal neuron loss and synaptic disruption (2010) (31)
Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia (2017) (31)
The apolipoprotein E gene in Binswanger's disease and vascular dementia (1996) (31)
Low Plasma ApoE Levels Are Associated with Smaller Hippocampal Size in the Alzheimer's Disease Neuroimaging Initiative Cohort (2014) (31)
Accumulation of intracellular amyloid-beta peptide (A beta 1-40) in mucopolysaccharidosis brains. (1999) (31)
Characterization of Parkinson’s disease using blood-based biomarkers: A multicohort proteomic analysis (2019) (31)
Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain (2013) (31)
Toxicologic and Carcinogenic Effects of the Type IV Phosphodiesterase Inhibitor RP 73401 on the Nasal Olfactory Tissue in Rats (1999) (31)
Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex (2006) (31)
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons (2018) (31)
A case study of an emerging visual artist with frontotemporal lobar degeneration and amyotrophic lateral sclerosis (2009) (31)
Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration (2019) (31)
An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline (2020) (31)
Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease. (1999) (30)
Neurofilament and chromogranin expression in normal and neoplastic neuroendocrine cells of the human gastrointestinal tract and pancreas (1990) (30)
Establishment of a cell model of ALS disease: Golgi apparatus disruption occurs independently from apoptosis (2008) (30)
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment (2015) (30)
New directions for frontotemporal dementia drug discovery (2008) (30)
Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype (2016) (30)
The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology (2019) (30)
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration (2020) (30)
Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists. (2011) (30)
Memory, executive, and multidomain subtle cognitive impairment (2015) (30)
A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers (2018) (30)
Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies (2017) (30)
Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2017) (29)
α-Synuclein in Familial Alzheimer Disease: Epitope Mapping Parallels Dementia With Lewy Bodies and Parkinson Disease (2001) (29)
Neuroanatomical correlates of selective downgaze paralysis (1981) (29)
Healthy brain aging: A meeting report from the Sylvan M. Cohen Annual Retreat of the University of Pennsylvania Institute on Aging (2008) (29)
Rational design of an animal model for alzheimer's disease: introduction of multiple human genomic transgenes to reproduce AD pathology in a rodent (1996) (29)
Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration (2018) (29)
Frontotemporal dementia and tauopathy (2001) (29)
Coordinate reduction in cell proliferation and cell death in mouse olfactory epithelium from birth to maturity (1997) (28)
Co-occurrence of Parkinson's disease with progressive supranuclear palsy (2002) (28)
Monoclonal antibodies to a rat nestin fusion protein recognize a 220-kDa polypeptide in subsets of fetal and adult human central nervous system neurons and in primitive neuroectodermal tumor cells. (1993) (28)
Plaque-Associated Neuronal Proteins: A Recurrent Motif in Neuritic Amyloid Deposits throughout Diverse Cortical Areas of the Alzheimer's Disease Brain (1994) (28)
T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease (2015) (28)
Dementia: a word to be forgotten. (2008) (28)
Neuronal activity modulates alpha-synuclein aggregation and spreading in organotypic brain slice cultures and in vivo (2020) (28)
TDP‐43 pathology occurs infrequently in multiple system atrophy (2011) (28)
T1ρ MRI in Alzheimer's Disease: Detection of Pathological Changes in Medial Temporal Lobe (2011) (28)
A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. (2018) (28)
Drosha Inclusions Are New Components of Dipeptide-Repeat Protein Aggregates in FTLD-TDP and ALS C9orf72 Expansion Cases (2015) (28)
Neurofilament proteins and human nervous system tumors. (1987) (27)
UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis (2019) (27)
Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease. (1999) (27)
Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in alzheimer’s disease (2002) (27)
Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease. (2019) (27)
Prominent perikaryal expression of alpha- and beta-synuclein in neurons of dorsal root ganglion and in medullary neurons. (2001) (27)
Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers (2021) (27)
Connexin‐43 and aquaporin‐4 are markers of ageing‐related tau astrogliopathy (ARTAG)‐related astroglial response (2018) (27)
Chondroid chordoma: a low-grade chondrosarcoma and its differential diagnosis. (1989) (27)
Apolipoprotein E ε4 allele distribution in alcoholic dementia and in Alzheimer's disease in Japan (1994) (27)
Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins (2014) (27)
TDP-43 pathology in a case of hereditary spastic paraplegia with a NIPA1/SPG6 mutation (2012) (26)
Pharmacokinetic, pharmacodynamic and metabolic characterization of a brain retentive microtubule (MT)-stabilizing triazolopyrimidine. (2015) (26)
Increased levels of fucosyltransferase IX and carbohydrate Lewisx adhesion determinant in human NT2N neurons (2007) (26)
Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor (2021) (26)
Antibodies to the β‐amyloid peptide cross‐react with conformational epitopes in human fibrinogen subunits from peripheral blood (1990) (26)
Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. (2019) (26)
Serum triglycerides in Alzheimer disease (2020) (26)
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
Effect of Genetic Risk Factors and Disease Progression on the Cerebrospinal Fluid Tau Levels in Alzheimer's Disease (1997) (26)
Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation (2004) (26)
Amyloid‐Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia (2016) (26)
Human teratomas express differentiated neural antigens. An immunohistochemical study with anti-neurofilament, anti-glial filament, and anti-myelin basic protein monoclonal antibodies. (1984) (25)
Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. (2020) (25)
Characterization of tau binding by gosuranemab (2020) (25)
Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration (2017) (25)
Familial frontotemporal dementia: from gene discovery to clinical molecular diagnostics. (2003) (25)
Human Olfactory Mucosa in Schizophrenia (1998) (25)
Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup. (2010) (25)
Design of comprehensive Alzheimer's disease centers to address unmet national needs (2010) (25)
Neurotrophin signal transduction in medulloblastoma (1997) (25)
Absence of C9ORF72 expanded or intermediate repeats in autopsy‐confirmed Parkinson's disease (2014) (25)
Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration (2019) (25)
Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease (2017) (25)
Heritability and genetic variance of dementia with Lewy bodies (2018) (25)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (25)
Characterization of hippocampal subfields using ex vivo MRI and histology data: Lessons for in vivo segmentation (2020) (25)
Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease (2019) (25)
Neurofilament breakdown products in degenerating rat and human peripheral nerves (1984) (25)
The developmental expression of neurofilament and glial filament proteins in the human pituitary gland: an immunohistochemical study with monoclonal antibodies. (1984) (25)
In vivo and in vitro models of medulloblastomas and other primitive neuroectodermal brain tumors of childhood (1994) (25)
The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer’s disease (2018) (25)
GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils (2017) (24)
Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy (2018) (24)
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease (2017) (24)
Milder Alzheimer's disease pathology in heart failure and atrial fibrillation (2017) (24)
Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome (2016) (23)
Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. (2006) (23)
Calcineurin Immunoreactivity in Alzheimer's Disease (1994) (23)
A comparison of Aβ amyloid pathology staging systems and correlation with clinical diagnosis (2014) (23)
Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment (2014) (23)
Evaluation of Oxetan-3-ol, Thietan-3-ol, and Derivatives Thereof as Bioisosteres of the Carboxylic Acid Functional Group. (2017) (23)
Continuity of neuropil threads with tangle-bearing and tangle-free neurons in Alzheimer disease cortex. A confocal laser scanning microscopy study. (1993) (23)
Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers. (2016) (23)
History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. (2014) (23)
A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model (2018) (23)
Synucleinopathies: a pathological and molecular review (2001) (23)
Neuropsychologic assessment in collaborative Parkinson’s disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson’s Disease Research at the University of Pennsylvania and the University of Washington (2013) (23)
Association of apolipoprotein epsilon 4 allele and neuropathologic findings in patients with dementia. (1995) (23)
Neuropathology and Cellular Pathogenesis of Spinocerebellar Ataxia Type 12 (2015) (22)
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease (2021) (22)
Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain (2019) (22)
Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort (2020) (22)
Human neurons that constitutively secrete Aβ do not induce Alzheimer's disease pathology following transplantation and long-term survival in the rodent brain (1995) (22)
Studies of childhood brain tumors using immunohistochemistry and microwave technology: methodological considerations (1994) (22)
A new consensus report on biomarkers for the early antemortem diagnosis of Alzheimer disease: current status, relevance to drug discovery, and recommendations for future research. (1998) (22)
ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration (2019) (22)
The growth and impact of Alzheimer disease centers as measured by social network analysis. (2014) (22)
Reduction of matrix metalloproteinase 9 (MMP-9) protects motor neurons from TDP-43-triggered death in rNLS8 mice (2019) (22)
Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease (2016) (22)
Association of CSF Aβ, amyloid PET, and cognition in cognitively unimpaired elderly adults (2020) (21)
Single-nuclei isoform RNA sequencing unlocks barcoded exon connectivity in frozen brain tissue (2022) (21)
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease (2018) (21)
alpha-Synuclein Pathology in Parkinson’s Disease and Related alpha-Synucleinopathies (2020) (21)
Myelin oligodendrocyte basic protein and prognosis in behavioral-variant frontotemporal dementia (2014) (21)
Beta-Amyloid peptide and amyloid precursor proteins in olfactory mucosa of patients with Alzheimer's disease, Parkinson's disease, and Down syndrome. (1995) (21)
Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition (2011) (21)
Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimer's disease. (2012) (21)
Comparison of In Vivo and Ex Vivo MRI of the Human Hippocampal Formation in the Same Subjects (2016) (21)
Rous-Whipple Award Lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it. (2005) (21)
Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire (2016) (20)
Elevated YKL-40 and low sAPPβ:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD (2018) (20)
Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study (2021) (20)
Converging Patterns of &agr;-Synuclein Pathology in Multiple System Atrophy (2018) (20)
α‐Synuclein Spread from Olfactory Bulb Causes Hyposmia, Anxiety, and Memory Loss in BAC‐SNCA Mice (2021) (20)
Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns (2020) (20)
Transgenic mouse models of tauopathies: Prospects for animal models of Pick’s disease (2001) (20)
Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies (2019) (20)
Distinct White Matter Changes Associated with Cerebrospinal Fluid Amyloid-β1-42 and Hypertension. (2018) (20)
Neurofilament-Rich Intraneuronal Inclusions Exacerbate Neurodegenerative Sequelae of Brain Trauma in NFH/LacZ Transgenic Mice (2000) (20)
Frequency and clinicopathological characteristics of presenilin 1 Gly206Ala mutation in Puerto Rican Hispanics with dementia. (2013) (20)
Diagnostic effectiveness of quantitative [18F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus (2014) (20)
Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. (2017) (20)
Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines. (2018) (19)
Cerebrospinal Fluid Tau Protein as a Potential Diagnostic Marker in Alzheimer’s Disease (1998) (19)
Dynamics of cell proliferation and cell death during the emergence of primitive neuroectodermal tumors of the immature central nervous system in transgenic mice. (1995) (19)
Vulnerability of the neuronal cytoskeleton in aging and Alzheimer disease: widespread involvement of all three major filament systems. (1990) (19)
Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine? (2020) (19)
Absence of Association of α1-Antichymotrypsin Polymorphisms with Alzheimer's Disease: A Report on Autopsy-Confirmed Cases (1998) (19)
p38 Mitogen-activated Protein Kinase-independent Induction of gadd45 Expression in Nerve Growth Factor-induced Apoptosis in Medulloblastomas* (2001) (19)
Memory, executive, and multi-domain subtle cognitive impairment: Clinical and biomarker finding (2015) (18)
Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. (2021) (18)
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau) (2019) (18)
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint (2019) (18)
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint (2019) (18)
Rates of lobar atrophy in asymptomatic MAPT mutation carriers (2019) (18)
Association of apolipoprotein ɛ4 allele and neuropathologic findings in patients with dementia (2004) (18)
Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease (2020) (17)
Cognitive Profile and Markers of Alzheimer Disease–Type Pathology in Patients With Lewy Body Dementias (2021) (17)
ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration (2020) (17)
CEREBROSPINAL FLUID TAU, Aβ, AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION (2018) (17)
THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY (2014) (17)
Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease (2021) (17)
Time of arrival of wheat germ agglutinin-HRP conjugates in superior colliculus after intraocular injections in the rat (1983) (17)
Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. (2017) (17)
Assessment of pathological tau proteins in frontotemporal dementias: qualitative and quantitative approaches. (2004) (17)
Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils. (2019) (17)
Effects of γ-Secretase Inhibition on the Amyloid β Isoform Pattern in a Mouse Model of Alzheimer’s Disease (2009) (17)
Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology (2021) (16)
Computational modeling of tau pathology spread reveals patterns of regional vulnerability and the impact of a genetic risk factor (2021) (16)
Is multiple system atrophy an infectious disease? (2018) (16)
Molecular Identification of AMY, an Alzheimer Disease Amyloid‐Associated Protein (2003) (16)
Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury (2004) (16)
Role of Cerebrospinal Fluid Biomarkers in Clinical Trials for Alzheimer's Disease Modifying Therapies (2014) (16)
Defining and predicting transdiagnostic categories of neurodegenerative disease (2019) (16)
A comprehensive screening of copy number variability in dementia with Lewy bodies (2019) (16)
PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding (2021) (16)
Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies. (2007) (16)
Immunohistochemical demonstration of phosphorylated and nonphosphorylated forms of human neurofilament subunits in human pulmonary carcinoids. (1987) (15)
A comprehensive assessment of benign genetic variability for neurodegenerative disorders (2018) (15)
Autopsy: Cutting Away the Myths (1992) (15)
Alzheimer's genetic risk is reduced in primary age‐related tauopathy: a potential model of resistance? (2018) (15)
Lewy Bodies: Purification from Diffuse Lewy Body Disease Brains a (1996) (15)
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease (2021) (15)
Production and Characterization of Two Ependymoma Xenografts (1996) (15)
An immunocytochemical study of normal and abnormal human cerebrospinal fluid with monoclonal antibodies to glial fibrillary acidic protein. (1986) (15)
In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics (2021) (15)
Familial pineoblastoma. Report of two cases. (1985) (15)
Tau epitopes in spinal cord neurofibrillary lesions in Chamorros of Guam (2000) (15)
Distinct brain‐derived TDP‐43 strains from FTLD‐TDP subtypes induce diverse morphological TDP‐43 aggregates and spreading patterns in vitro and in vivo (2021) (15)
Serum triglycerides in Alzheimer’s disease: Relation to neuroimaging and CSF biomarkers (2018) (15)
High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration (2015) (15)
Astroglial tau pathology alone preferentially concentrates at sulcal depths in chronic traumatic encephalopathy neuropathologic change (2020) (15)
Tau deposition patterns are associated with functional connectivity in primary tauopathies (2022) (14)
METHOD COMPARISON OF AB(1-42) MEASURED IN HUMAN CEREBROSPINAL FLUID SAMPLES BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, THE INNO-BIA ALZBIO3 ASSAY, AND THE ELECSYS® B-AMYLOID(1-42) ASSAY (2016) (14)
Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. (2019) (14)
Brain degeneration linked to "fatal attractions" of proteins in Alzheimer's disease and related disorders. (2001) (14)
Exploring human/animal intersections: Converging lines of evidence in comparative models of aging (2008) (14)
Nonlinear Z-score modeling for improved detection of cognitive abnormality (2019) (14)
Expression of β-amyloid precursor protein in the developing human spinal cord (1994) (14)
Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases (2011) (14)
Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease (1999) (14)
A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research (2012) (14)
Publisher Correction: Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease (2018) (13)
Cognitive reserve in frontotemporal degeneration (2016) (13)
Abundance of Apoptotic Neoplastic Cells in Diagnostic Biopsy Samples Is not a Prognostic Factor in Childhood Primitive Neuroectodermal Tumors of the Central Nervous System (2001) (13)
Neuroectodermal tumors of the peripheral and the central nervous system share neuroendocrine N-CAM-related antigens with small cell lung carcinomas (2004) (13)
Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice (2021) (13)
Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) (13)
Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau (2020) (13)
Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers (2019) (13)
Synthesis and characterization of high affinity fluorogenic α-synuclein probes. (2020) (13)
Hippocampal subfield pathologic burden in Lewy body diseases vs. Alzheimer’s disease (2020) (13)
Hereditary tauopathies and idiopathic frontotemporal dementias (2004) (13)
Neural and neuroendocrine phenotype of neuroblastomas, ganglioneuroblastomas, ganglioneuromas and mature versus embryonic human adrenal medullary cells. (1991) (13)
Tau pathology associates with in vivo cortical thinning in Lewy body disorders (2020) (12)
Is the Initial Insult in Parkinson's Disease and Dementia with Lewy Bodies a Neuritic Dystrophy? (2003) (12)
LRP10 in α-synucleinopathies (2018) (12)
Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum (2020) (12)
Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers. (2019) (12)
Multiple pathologies in a patient with a progressive neurodegenerative syndrome (2005) (12)
Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding (2015) (12)
Statins and Cognition in Parkinson's Disease. (2017) (12)
Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His (2015) (12)
Empiric Methods to Account for Pre-analytical Variability in Digital Histopathology in Frontotemporal Lobar Degeneration (2019) (12)
Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants (2019) (12)
Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice (2016) (12)
Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults (2017) (12)
Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology (2021) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
Anti-neurofilament monoclonal antibodies: Reagents for the evaluation of human neoplasms (2004) (11)
Role of brain infarcts in behavioral variant frontotemporal dementia Clinicopathological characterization in the National Alzheimer's Coordinating Center database (2015) (11)
The cellular and molecular biology of medulloblastoma. (1995) (11)
Selective expression of epitopes in multiphosphorylation repeats of the high and middle molecular weight neurofilament proteins in Alzheimer neurofibrillary tangles. (1989) (11)
Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD (2021) (11)
Presence of an alpha-melanocyte-stimulating hormone-like epitope in the 150,000 dalton neurofilament subunit from diverse regions of the central nervous system: an immunohistochemical and immunoblot study in guinea pig. (1985) (11)
Commentary on “Optimal design of clinical trials for drugs designed to slow the course of Alzheimer℉s disease.” Biochemical biomarkers of late-life dementia (2006) (11)
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease (2020) (11)
Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro (2021) (11)
Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery (2006) (11)
Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery (2021) (11)
Tau immunotherapy is associated with glial responses in FTLD-tau (2021) (11)
In situ blood-brain barrier permeability of a C-10 paclitaxel carbamate. (2008) (11)
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points. (2019) (11)
Many roads to Parkinson's disease neurodegeneration: Head trauma—A road more traveled than we know? (2013) (11)
Poly (ADP-ribose) Interacts With Phosphorylated α-Synuclein in Post Mortem PD Samples (2021) (11)
Tauopathy with hippocampal 4‐repeat tau immunoreactive spherical inclusions: a report of three cases (2018) (11)
Featured Articles National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (2012) (11)
TEMPORAL PROGRESSION OF HIPPOCAMPAL ATROPHY AND APOLIPOPROTEIN E GENE IN ALZHEIMER'S DISEASE (1996) (10)
Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. (2020) (10)
Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. (2003) (10)
Tau proteins and their significance in the pathobiology of Alzheimer's disease (1995) (10)
Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions (2021) (10)
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives (2021) (10)
Long-term behavioral sequelae of lateral fluid-percussion brain injury in the rat (1994) (10)
PENN Neurodegenerative Disease Research – In the Spirit of Benjamin Franklin (2007) (10)
Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual (2007) (10)
Expression of vimentin, glial filament, and neurofilament proteins in primitive childhood brain tumors (1985) (10)
Ex vivo MRI and histopathology detect novel iron-rich cortical inflammation in frontotemporal lobar degeneration with tau versus TDP-43 pathology (2021) (10)
Diseases: New Concepts of Pathogenesis and Their Therapeutic Implications (2006) (10)
Fatal Attractions: Protein Aggregates in Neurodegenerative Disorders (2000) (10)
P2-250 Short-term accumulation of beta amyloid in axonal pathology following traumatic brain injury in human (2004) (10)
Genome-wide association study and functional validation implicates JADE1 in tauopathy (2021) (10)
Partial deficit of pantothenate kinase 2 catalytic activity in a case of tremor‐predominant neurodegeneration with brain iron accumulation (2006) (10)
University of Dundee TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse (9)
Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology (2021) (9)
INCLUSION OF PATIENTS WITH ALZHEIMER'S DISEASE PATHOLOGY IN SOLANEZUMAB EXPEDITION 3 USING FLORBETAPIR PET IMAGING OR INNO-BIA ALZBIO3 CSF Aβ1-42 (2014) (9)
LRP10 in α-synucleinopathies (2018) (9)
Pathobiological features in neurodegenerative diseases: an overview (2004) (9)
In pursuit of the molecular neuropathology of schizophrenia. (1995) (9)
Evaluation of the Structure-Activity Relationship of Microtubule-Targeting 1,2,4-Triazolo[1,5-a]pyrimidines Identifies New Candidates for Neurodegenerative Tauopathies. (2021) (9)
Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497 (2014) (9)
Neocortical β-amyloid area is associated with dementia and APOE in the oldest-old (2013) (9)
Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis (2020) (9)
The Alzheimer's Brain (2005) (9)
AMY plaques in familial AD (2000) (9)
APOE ε4 allele in Alzheimer's and non-Alzheimer's dementias (1996) (9)
Phospholipase pathway in Alzheimer's disease brains: decrease in Galphai in dorsolateral prefrontal cortex. (1999) (9)
Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery. (2002) (9)
Acalculia in Autopsy-Proven Corticobasal Degeneration (2011) (8)
Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum (2021) (8)
Association of ABCA 2 expression with determinants of Alzheimer ' s disease (2004) (8)
Spatial relationship of AMY protein deposits and different species of Abeta peptides in amyloid plaques of the Alzheimer disease brain. (1999) (8)
A novel GRN mutation (GRN c.708+6_+9delTGAG) in frontotemporal lobar degeneration with TDP-43-positive inclusions: clinicopathologic report of 6 cases. (2014) (8)
Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes (2021) (8)
Reply: LATE to the PART-y. (2019) (8)
FUS pathology deﬁnes the majority of tau- and TDP-43-negative frontotemporal lobar degeneration (2010) (8)
COllaborative Neuropathology NEtwork Characterizing ouTcomes of TBI (CONNECT-TBI) (2021) (8)
ADNC-RS, a clinical-genetic risk score, predicts Alzheimer’s pathology in autopsy-confirmed Parkinson’s disease and Dementia with Lewy bodies (2020) (7)
Meeting summary--cell biology of Parkinson's disease and related neurodegenerative disorders. (2003) (7)
Dopamine neurons exhibit emergent glutamatergic identity in Parkinson's disease. (2021) (7)
Microtubule-Stabilizing Agents for Alzheimer’s and Other Tauopathies (2016) (7)
Genetic predictors of survival in behavioral variant frontotemporal degeneration (2019) (7)
The diabetes drug liraglutide ameliorates insulin resistance in the hippocampal formation of Alzheimer's disease (AD) cases (2011) (7)
Global democratic consensus on neuropathological disease criteria (2002) (7)
TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss (2022) (7)
Shapes of the Trajectories of Five Major Biomarkers of Alzheimer’s Disease (2013) (7)
Evaluation of the cyclopentane-1,2-dione as a potential bio-isostere of the carboxylic acid functional group. (2014) (7)
Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort (2020) (7)
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice (2020) (7)
Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges? (2019) (7)
Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays (2020) (7)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture (2020) (7)
Correction of microtubule defects within Aβ plaque‐associated dystrophic axons results in lowered Aβ release and plaque deposition (2020) (7)
Leptomeningeal carcinomatosis presenting as eosinophilic meningitis. (1986) (7)
Common threads in neurodegenerative disorders of aging (2006) (6)
Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. (2020) (6)
Disease-, region- and cell type specific diversity of α-synuclein carboxy terminal truncations in synucleinopathies (2021) (6)
Erratum to: Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) (2015) (6)
TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy (2021) (6)
Short Communication Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by a -, b -, and g -Synuclein Neuropathology (2000) (6)
Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice (2020) (6)
Signature laminar distributions of pathology in frontotemporal lobar degeneration (2022) (6)
Protease resistant prion proteins are not present in sporadic “poor outcome” schizophrenia (1999) (6)
Interpretable deep learning of myelin histopathology in age-related cognitive impairment (2022) (6)
Autosomal dominant and sporadic late onset Alzheimer disease share a common in vivo pathophysiology. (2022) (6)
Protein mis-folding emerges as a "drugable" target for discovery of novel therapies for neuropsychiatric diseases of aging. (2004) (6)
Schizophrenia and its dementia (2004) (6)
How Will Aducanumab Approval Impact AD Research? (2021) (6)
Building an Ex Vivo Atlas of the Earliest Brain Regions Affected by Alzheimer's Disease Pathology (2020) (6)
Detection of Alzheimer Disease Pathology in Patients Using Biochemical Biomarkers: Prospects and Challenges for Use in Clinical Practice. (2019) (6)
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4 (2022) (6)
Potent, long-acting cyclopentane-1,3-Dione thromboxane (A2)-receptor antagonists. (2014) (5)
Plasma Phosphorylated Tau181 is a Biomarker of Alzheimer's Disease Pathology and Associated with Cognitive and Functional Decline (2022) (5)
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
Poly (ADP-ribose) induces α-synuclein aggregation in neuronal-like cells and interacts with phosphorylated α-synuclein in post mortem PD samples (2020) (5)
Apolipoprotein E epsilon 4 allele distribution in alcoholic dementia and in Alzheimer's disease in Japan. (1994) (5)
Head and Neck and Plastic Surgery A Targeted Problem and Its Solution (1993) (5)
Burden of Neurodegenerative Diseases in a Cohort of Medical Examiner Subjects * (2010) (5)
Diagnostic Accuracy of Amyloid and FDG PET in Pathologically-Confirmed Dementia (S8.005) (2014) (5)
Expression of beta-amyloid precursor protein in the developing human spinal cord. (1994) (5)
XIVth International Congress of Neuropathology Scientific Programme (2000) (5)
Inter-laboratory variation when using a unified test procedure for INNO-BIA AlzBio3 (2013) (5)
Longitudinal naming and repetition relates to AD pathology and burden in autopsy‐confirmed primary progressive aphasia (2021) (5)
Genetic prediction of impulse control disorders in Parkinson's disease (2022) (5)
Reply to "Transplanted dopaminergic neurons: More or less?" (2001) (5)
A framework for informing segmentation of in vivo MRI with information derived from ex vivo imaging: Application in the medial temporal lobe (2016) (5)
Alzheimer's disease centers and the dementias of aging program of the national institute on aging: a brief overview. (2001) (5)
LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons (2021) (5)
Small neuronal size in hippocampal subfields that mediate cortical-hippocampal interactions (1994) (5)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
In vivo optical and PET detections of fibrillar tau lesions in a mouse model of tauopathies (2009) (5)
Analysis of cerebrospinal fluid mitochondrial DNA levels in Alzheimer disease (2014) (5)
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting (2022) (5)
Plasma Apolipoprotein A 1 as a Biomarker for Parkinson ' s Disease (2013) (4)
Increased isoprostane biosynthesis in alzheimer's disease: Correlation of a specific non invasive index of lipid peroxidation with disease severity (2000) (4)
CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology (2022) (4)
C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts (2020) (4)
Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90 (2022) (4)
The Alzheimer’s Disease Metabolome: Effects of Sex and APOE ε4 genotype (2019) (4)
Drug discovery in neurodegenerative diseases. (2005) (4)
Mechanisms of Neuron Death in Neurodegenerative Diseases of the Elderly (1998) (4)
Mapre2 as a novel Alzheimer's disease target gene from gwas of CSF amyloid beta 1-42, tau and hyperphosphorylated tau in the ADNI cohort (2015) (4)
Insoluble Tau From Human FTDP-17 Cases Exhibit Unique Transmission Properties In Vivo. (2020) (4)
Animal models of neurodegenerative dementing disorders other than Alzheimer's disease (2004) (4)
Comparison of Cerebrospinal Fluid Levels of Tau and A 1-42 in Alzheimer's Disease and Frontotemporal Degeneration Using Two Analytical Platforms (P02.055) (2012) (4)
INTRACEREBRAL INJECTION OF PREFORMED SYNTHETIC TAU FIBRILS INITIATES WIDESPREAD TAUOPATHY AND NEURONAL LOSS IN THE BRAINS OF TAU TRANSGENIC MICE (2014) (4)
Alzheimer disease Cerebrospinal Fluid biomarker in Cognitively Normal Subjects : Multicenter 1 Study 2 (2015) (4)
Astrocyte senescence as a component of Alzheimer's disease (2013) (4)
3D Mapping of Neurofibrillary Tangle Burden in the Human Medial Temporal Lobe (2021) (4)
Association of plasma and cortical beta-amyloid is modulated by APOE ε4 status. (2014) (4)
Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis (2022) (4)
Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization (2022) (4)
Ordering of Alzheimer's disease biomarkers (2011) (4)
Clinical and Pathological Implications (2017) (4)
Novel probes for imaging amyloid: Iodinated benzothiazole derivatives (2001) (3)
Common Variants Near ZIC1 and ZIC4 in Autopsy‐Confirmed Multiple System Atrophy (2022) (3)
Cytoskeletal proteins and neuronal tumors (1988) (3)
Disruption of Large-scale Neural Networks in Non-Fluent/Agrammatic Primary Progressive Aphasia☆ (2013) (3)
Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. (2016) (3)
Biochemistry of neurodegeneration [2] (multiple letters) (2001) (3)
Alzheimer’s disease biomarkers: walk with deliberate haste, don’t run blithely on? (2013) (3)
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration (2022) (3)
APOE effect on Alzheimer’s biomarkers in older adults with significant memory concern (2015) (3)
Short Communication Full-Length Amyloid-f3(1-42(43)) and Amino-Terminally Modified and Truncated Amyloid-(42(43) Deposit in Diffuse Plaques (2007) (3)
THE ABNORMAL PHOSPHORYLATION OF TAU AT SER396 IN ALZHEIMERʼS DISEASE RECAPITULATES PHOSPHORYLATION DURING DEVELOPMENT AND CONTRIBUTES TO REDUCED MICROTUBULE BINDING (1993) (3)
Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer’s disease (2022) (3)
Tau and α-Synuclein in Neurodegenerative Diseases (2001) (3)
Alterations in metabolic pathways and networks in mild cognitive impairment and early Alzheimer's disease (2013) (3)
Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment (2022) (3)
Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. (2020) (3)
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker (2013) (3)
ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER’S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS (2018) (3)
Neuropathologic substrates of Parkinson's disease dementia (S52.002) (2012) (3)
Neurodegenerative Diseases: Frontotemporal dementia with parkinsonism linked to Chromosome 17 (2005) (3)
Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis (2020) (3)
Alzheimer disease A68 proteins injected into rat brain induce codeposits of j8-amyloid, ubiquitin, and al-antichymotrypsin (tau/senile (2005) (3)
Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy (2018) (3)
Frontotemporal dementia: Report of a familial case (2001) (3)
The cellular and molecular correlates of cognitive impairments in the Alzheimer's disease brain (1996) (3)
LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice (2019) (3)
Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease (2022) (3)
The Neuropathology of Dementia: Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of diseases with α-synuclein inclusions (2004) (3)
Transforming CSF Aβ42 measures of brain beta-amyloid into calculated PIB (PIBcalc) units (2010) (3)
Traumatic brain injury and post‐traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers (2022) (3)
Acceleration of brain atrophy rates with advancing cognitive deterioration from normal aging to MCI to Alzheimer's disease (2011) (3)
Research on the brain. (2003) (3)
Commentary on “Diagnosis of Alzheimer's disease: Two decades of progress” Alzheimer's disease research: New opportunities for early diagnosis and drug discovery (2005) (3)
Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration (2022) (3)
Predicting brain amyloidosis in MCI using clinical, cognitive, imaging and peripheral blood protein measures (2012) (3)
Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease (2020) (2)
High‐resolution postmortem MRI reveals TDP‐43 association with medial temporal lobe subregional atrophy (2020) (2)
In vivo optical and PET detections of fibrillar tau lesions in a mouse model of tauopathies (2009) (2)
Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis (2022) (2)
Targeted lipidomic pathway-guided genetic association with Alzheimer's disease–relevant endophenotypes (2013) (2)
Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer’s disease (2015) (2)
TREM2 risk variants are associated with atypical Alzheimer’s disease (2022) (2)
THE IMMUNOPHENOTYPE OF CENTRAL PRIMITIVE NEUROECTODERMAL TUMORS (PNETS): 174 (1989) (2)
Joint ex vivo MRI and histology detect iron-rich cortical gliosis in Tau and TDP-43 proteinopathies (2021) (2)
Absence of C 9 ORF 72 expanded or intermediate repeats in autopsy confirmed Parkinson Disease (2014) (2)
Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. (2022) (2)
3D Mapping of TAU Neurofibrillary Tangle Pathology in the Human Medial Temporal Lobe (2020) (2)
Hallucinations and Development of Dementia in Parkinson's Disease. (2020) (2)
Hippocampal subfield pathologic Burden in Lewy body diseases versus Alzheimer’s disease (2021) (2)
Tau pathology spreads between anatomically-connected regions of the brain and is modulated by a LRRK2 mutation (2020) (2)
Defined neurofilament , T , and fi-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques ( cytoskeletal proteins / A 4 protein / neurodegenerative disease ) (2)
Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias. (2022) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology (2021) (2)
Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain (2013) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2018) (2)
Erratum: Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2 (Journal of Neuroscience (January 19, 2005) (689-698)) (2005) (2)
Domain structure of neurofilament subunits as revealed by monoclonal antibodies (1985) (2)
Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein (2023) (2)
Gray Matter Segmentation in Ultra High Resolution 7 Tesla ex vivo T2w MRI of Human Brain Hemispheres (2021) (2)
Clinicopathological Correlations of AD Neuropathology in the Logopenic Variant of Primary Progressive Aphasia (S39.002) (2016) (2)
O1-04-04 The Alzheimer’s disease neuroimaging initiative: Progress report (2007) (2)
Machine learning suggests polygenic contribution to cognitive dysfunction in amyotrophic lateral sclerosis (2020) (2)
Ventricular maps in 804 subjects correlate with cognitive decline, CSF pathology, and imminent Alzheimer's disease (2010) (2)
Thorn-shaped astrocytes in the depth of cortical sulci in Western Pacific ALS/Parkinsonism-Dementia complex (2020) (2)
Subtypes based on CSF and MRI markers in normal elderly predict cognitive decline (2010) (2)
Practical approach to pathological diagnosis (2004) (2)
Primary or secondary prevention for AD: who cares? (2012) (2)
COMBINING CSF AB42 AND PET FLORBETAPIR TO PREDICT DIAGNOSIS, TAU, ATROPHY, AND COGNITION (2014) (2)
[11C]PBB3 PET VISUALIZES TAU AGGREGATES IN PATIENTS WITH FTDP-17 MAPT GENE MUTATION (2016) (2)
Self- versus informant-based cognitive complaints: Relation of E-Cog scores to imaging, biomarkers and clinical Status in ADNI-2 (2013) (2)
Redox signaling directly regulates TDP-43 via cysteine oxidation and disulfide cross-linking (2011) (2)
Atypical Alzheimer's disease in an elderly United States resident with amyotrophic lateral sclerosis and pathological tau in spinal motor neurons (2014) (2)
Purification of Lewy Bodies and Identification of α-Synuclein as a Major Component of Lewy Bodies (2000) (2)
Tracking tau fibrillogenesis and consequent primary phagocytosis of neurons mediated by microglia in a living tauopathy model (2020) (2)
Transmission of neuronal and glial tau pathology: new models for developing disease modifying therapy for Alzheimer's and related tauopathies (2016) (2)
666 Microtubule-associated protein tau in cerebrospinal fluid: Implications for a potential diagnostic marker in Alzheimer's disease (1996) (2)
NONLINEAR N-SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM THE NATIONAL ALZHEIMER’S COORDINATING CENTER (NACC) DATASET (2018) (2)
Associations of phosphorylated tau pathology with whole-hemisphere ex vivo morphometry in 7 tesla MRI. (2022) (2)
O1-04-01 Transgenic mouse models of TAU pathology in astrocytes leading to nervous system degeneration (2004) (1)
CHARACTERISTICS AND PROGRESS ON THE INITIAL 209 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL (2017) (1)
Living Longer and Paying the Price? (2005) (1)
ER stress in Alzheimer's disease and PSP: Common disease mechanism? (2012) (1)
Tau focused drug discovery for Alzheimer’s disease and related Neurodegenerative Tauopathies (2006) (1)
Novel ex vivo MRI atlas of the medial temporal lobe can be used to characterize structural changes due to Alzheimer’s disease pathology (2020) (1)
Changes in plasma based biomarkers in Alzheimer's disease, mild cognitively impaired and aged matched normal controls from the ADNI cohort (2011) (1)
Calsyntenin‐1 is a cerebrospinal fluid marker of frontotemporal dementia‐related synapse degeneration (2021) (1)
Injury and Disease Linkages Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative * (2014) (1)
Clinical and multimodal biomarker correlates of ADNI neuropathological findings (2013) (1)
Immune-related genetic enrichment in frontotemporal dementia (2017) (1)
Epitope Map of Neurofilament Protein Domains (2007) (1)
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition (2014) (1)
CEREBROSPINAL FLUID LEVELS OF AMYLOID BETA AND TAU AS ENDOPHENOTYPES REVEAL NOVEL VARIANTS POTENTIALLY INFORMATIVE FOR ALZHEIMER'S DISEASE (2016) (1)
P4-426 Effect of chronic lithium treatment on an animal model of tauopathies (2004) (1)
Transgenic mouse models of neurodegenerative disease (2004) (1)
PERFORMANCE EVALUATION OF NEW ABSORBANCE-BASED ELISAS FOR MEASURING DIFFERENT ALPHA-SYNUCLEIN (A-SYN) SPECIES IN CSF AND PLASMA (2016) (1)
Axonal Transport and Neurodegenerative Diseases (2009) (1)
Pathogenesis of dementia: updating the role of synuclein pathology in sporadic and hereditary Alzheimer’s disease (2001) (1)
Studies of a Human Neuron-Like Cell Line in Stroke and Spinal Cord Injury (2003) (1)
Self-reported versus informant-based cognitive complaints: Relation of E-Cog scores to imaging biomarkers and clinical status in ADNI-2 (2013) (1)
Retraction: Winton et al., Intraneuronal APP, Not Free Aβ Peptides in 3xTg-AD Mice: Implications for Tau Versus Aβ-Mediated Alzheimer Neurodegeneration (2015) (1)
P3-093: Characterization of CSF Aβ1-42, Tau and p-Tau181p concentrations at baseline in Alzheimer's disease neuroimaging initiative study patients (2008) (1)
Chapter 11 – Microtubule Stabilization (2016) (1)
Alzheimer’s Disease, Parkinson’s Disease, and Frontotemporal Dementias: Different Manifestations of Protein Misfolding (2008) (1)
Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting (2022) (1)
Relationship between CSF and plasma proteomic data in the ADNI-1 cohort (2012) (1)
Mechanisms of oxidative damage in neurodegenerative synucleinopathies (2000) (1)
A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model (2018) (1)
Cerebrospinal fluid biomarker panel of synaptic dysfunction in Alzheimer's disease and other neurodegenerative disorders. (2022) (1)
Cerebrospinal fluid neurogranin in non‐amnestic and amnestic Alzheimer’s disease (2021) (1)
Single-nuclei isoform RNA sequencing reveals combination patterns of transcript elements across human brain cell types (2021) (1)
b-synuclein modulates a-synuclein neurotoxicity by reducing a-synuclein protein expression (2006) (1)
Atrial Fibrillation in Patients with Neuropathological Diagnosis of Primary Alzheimer’s Disease (I9-5A) (2015) (1)
Importance of coincident neurodegenerative diseases (2013) (1)
Distinct Tau Gene Mutations Induce Specific Dysfunctions/Toxic Properties in Tau Proteins Associated With Specific FTDP-17 Phenotypes (2000) (1)
Deep learning pipeline for cortical gray matter segmentation and thickness analysis in Ultra High Resolution T2w 7 Tesla Ex vivo MRI across neurodegenerative diseases reveals associations with underlying neuropathology (2022) (1)
Elevated plasma phosphorylated tau in amyotrophic lateral sclerosis relates to lower motor neuron dysfunction (2022) (1)
Abundant copathologies of polyglucosan bodies, frontotemporal lobar degeneration with TDP‐43 inclusions and ageing‐related tau astrogliopathy in a family with a GBE1 mutation (2022) (1)
Biomarker predictors of cognitive decline in healthy older participants in the Alzheimer's Disease Neuroimaging Initiative (2010) (1)
Cerebrospinal Fluid Biomarkers and [11C]Pittsburgh Compound-B PET Concordance in Alzheimer Disease vs. Frontotemporal Dementia Syndromes (P1.213) (2015) (1)
Review Article Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research (2014) (1)
Biochemical Markers of Neurodegenerative Diseases: τ and Synucleins (2000) (1)
383. The dementia of schizophrenia: Antemortem and postmortem studies (1996) (1)
Diagnostic effectiveness of quantitative [18F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus (2014) (1)
Prospective quality-control monitoring in the context of a clinical trial (2015) (1)
Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration (2017) (1)
Clinical and Survival Profiles of Patients with Frontotemporal Dementia and Motor Neuron Disease (2009) (1)
CHEMICAL AND IMMUNOLOGICAL HETEROGENEITY OF FIBRILLAR AMYLOID IN PLAQUES: 80 (1995) (1)
A TOMM40 SNP in APOE-ε4 noncarriers increases risk for multiple types of dementia (2013) (1)
Tau spreads across connected brain regions in progressive supranuclear palsy and corticobasal syndrome (2021) (1)
VALIDATION STUDIES OF NEUROFILAMENT LIGHT AND Aβ-40 AND Aβ-42 ASSAYS IN HUMAN PLASMA USING THE SIMOA PLATFORM (2019) (1)
Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases (2017) (1)
ASSOCIATION OF PLASMA LEPTIN/ADIPONECTIN RATIO IN MEN WITH CSF BIOMARKERS IN THE ADNI-1 COHORT (2014) (1)
Neocortical beta-amyloid area, but not CERAD plaque stage, is associated with dementia status and Apolipoprotein E (APOE) genotype in the oldest old (2010) (1)
Brain insulin resistance demonstrated in Alzheimer's disease is closely associated with elevated IRS-1 pS and cognitive deficits (2011) (1)
Neuroimaging-Based Staging of Pathological Spread in Patients with Known Tau Pathology (P4.085) (2015) (1)
Mutations of Human Cu, Zn Superoxide Dismutase Expressed in Transgenic Mice Cause Motor Neuron Disease (1996) (1)
DERIVING A CUT-OFF FOR THE ELECSYS® β-AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER’S DISEASE (AD) (2017) (1)
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies (2013) (1)
Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease (2021) (1)
Novel CSF biomarkers for frontotemporal lobar degeneration with lesions immunoreactive to TDP-43 (FTLD-TDP) (1)
Author Correction: An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer’s disease (2020) (1)
Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated. (2023) (1)
P2-112 Selective suppression of NF-κB by indomethacin modulates Aβlevels and deposition but not metabolism in a model of Alzheimer disease (2004) (1)
Association of the MAPT with Cerebrospinal Fluid Phosphorylated Tau Levels in Frontotemporal Degeneration (S38.008) (2014) (1)
Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology (2021) (1)
Deep Learning for Ultra High Resolution T2‐weighted 7 Tesla Ex vivo Magnetic Resonance Imaging Reveals Differential Subcortical Atrophy across Neurodegenerative Diseases (2022) (1)
Divergent Histopathological Networks of Frontotemporal Degeneration Proteinopathy Subytpes (2022) (1)
Long-term Outcomes of Parkinson's Disease Patients with Normal Cognition. (P5.260) (2014) (1)
Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer’s disease from normal cognitive aging (2013) (1)
Erratum: Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. (Brain (2019) 142, (1503–1527) DOI: 10.1093/brain/awz099) (2019) (1)
PARIETAL LOBE CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH LOWER CEREBROSPINAL FLUID BETA AMYLOID 1-42 IN PATIENTS WITH SPORADIC AD (2018) (1)
Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau (2021) (1)
DIAGNOSTIC EFFECTIVENESS OF QUANTITATIVE [18F]FLUTEMETAMOL PET IMAGING IN SUBJECTS WITH NORMAL PRESSURE HYDROCEPHALUS USING BIOPSY HISTOPATHOLOGY STANDARD OF TRUTH FOR DETECTION OF FIBRILLAR AMYLOID B (2014) (1)
94 TAU PROTEIN AND TAUOPATHY (2002) (1)
Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U (2013) (1)
APOLIPOPROTEIN E EPSILON 4 ALLELE AND SCHIZOPHRENIA. AUTHORS' REPLY (1997) (1)
Neurodegenerative Diseases: Frontotemporal lobar degeneration (2005) (1)
Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders (2017) (1)
Genome-wide association study of CSF biomarkers amyloid beta 1-42, tau and tau phosphorylated at threonine 181 in the ADNI cohort (2010) (1)
Morphometric methods and dementia (2004) (1)
CSF biomarker and PIB-PET—derived beta-amyloid signature predicts Brain metabolism, grey matter and cognitive changes in non-demented subjects (2011) (1)
Transgenic mice overexpressing the shortest human tau isoform develop a progressive tauopathy (2001) (1)
Sensitivity and Specificity of Clinical Criteria for 4-Repeat Tauopathies in Autopsy-Confirmed Cases (S27.003) (2018) (1)
Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology (2022) (1)
Animal Models of Cerebral Ischemia (1998) (1)
Improving analytical performance of immunoassay methods (2013) (0)
Plasma phosphorylated tau181 predicts cognitive and functional decline (2022) (0)
Tau Gene Mutations in FTDP-17 Syndromes (2007) (0)
The differences in CD33 protein expression for AA and EA suggest that race and gender play a role in CD33 expression, the gene product of the CD33 susceptibility locus. P3-055 PREECLAMPSIA DURING PREGNANCYAND ALZHEIMER’S DISEASE LATER IN LIFE (2013) (0)
NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET (2014) (0)
TDP-43 and mixed pathologies in normal cognition, mild cognitive impairment and dementia (2013) (0)
COllaborative Neuropathology NEtwork Characterizing ouTcomes of TBI (CONNECT-TBI) (2021) (0)
Aminobenzothiazoles as inhibitors of tau-fibril formation in Alzheimer's and other neurodegenerative diseases (2008) (0)
Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer’s disease (2017) (0)
Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal dementia and GRN mutations : a genome-wide association study (2018) (0)
Author Correction: Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2018) (0)
Pairwise gene-protein association analysis on CSF proteomics in the ADNI-1 cohort (2012) (0)
CSF p‐Tau/AΒ40 ratio adjusts for the variance of CSF production and predicts brain tau accumulation in Alzheimer’s disease (2020) (0)
Longitudinal evaluation of familial frontotemporal dementia subjects (LEFFTDS): Subject characteristics, aims, and methodology (2015) (0)
MULTIVARIATE GENOME-WIDE ASSOCIATION STUDY OF CSF BIOMARKERS FOR ALZHEIMER’S DISEASE IDENTIFIES VARIANTS IN HLA CLASS I REGION PROVIDING FURTHER EVIDENCE FOR THE ROLE OF IMMUNE FUNCTION (2018) (0)
Quantifying effects of Alzheimer ’ s disease on the human hippocampus using an ex vivo atlas combining MRI and histology (2018) (0)
Review Articles The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans (2010) (0)
Low serum levels of APOE associate with hippocampal atrophy in the ADNI cohort (2011) (0)
α-SYNUCLEIN IS A COMPONENT OF LEWY BODIES (1998) (0)
schizophrenia present in sporadic ' ' poor outcome ' ' Protease resistant prion proteins are not (1998) (0)
P2-058 Synapse loss is an early pathological manifestation in a tauopthy model, P301S mutant tau transgenic mice (2004) (0)
P1-302 Implications of dopamine-induced modificationsof alpha-synuclein protein in the pathogenesis of Parkinson's disease (2004) (0)
Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology (2021) (0)
A neuroattenuated ICP 34 . 5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system (1998) (0)
Biochemical Analysis of (cid:1) Proteins in Argyrophilic Grain Disease, Alzheimer’s Disease, and Pick’s Disease A Comparative Study (2002) (0)
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
GENETIC INFLUENCE ON LEVELS OF TARGETED METABOLITES ASSOCIATED WITH ALZHEIMER’S DISEASE (2016) (0)
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease (2019) (0)
Investigator and Core Facility Contact Information (2012) (0)
ALZHEIMER’S DISEASE Advances in Genetics, Molecular and Cellular Biology ALZHEIMER’S DISEASE Advances in Genetics, Molecular and Cellular Biology (2013) (0)
Neuropsychiatric symptoms associated with the APOE-ε4 allele in subjects with mild cognitive impairment in the DESCRIPA and ADNI cohorts (2012) (0)
The Power of Multimodal Neuroimaging Biomarkers for Clinical Trial Screening (P06.034) (2013) (0)
Genetic & Neuroanatomic Associations in Sporadic Frontotemporal Lobar Degeneration (I5-1.002) (2014) (0)
Tau Phosphorylation and Dephosphorylation in the Pathogenesis of Alzheimer’s Disease (1996) (0)
Empirical pathological staging and subtyping of TDP‐43 proteinopathies (2022) (0)
THE LANGUAGE VARIANTS OF FRONTOTEMPORAL LOBAR DEGENERATION (2019) (0)
Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies (2019) (0)
Progressive Multifocal Leukoencephalopathy: In Situ JC Viral Detection with Terminally Biotin-Labeled, Site Specific Oligonucleotide Probes (1994) (0)
Neuroscience: Stress speeds up brain degeneration (2011) (0)
Linking histology to post‐mortem 7T MRI measures of neurodegeneration (2022) (0)
WHOLE GENE-BASED ASSOCIATION OF BASELINE PLASMA HOMOCYSTEINE IN THE ADNI-1 COHORT (2014) (0)
147 INDUCTION AND DIFFERENTIAL LOCALIZATON OF NEUROFILAMENT PROTEINS IN CULTURED RAT PC12 PHECHROMOCYTOMA CELLS AFTER EXPOSURE TO NGF (1981) (0)
Regional distribution of tau pathology in subfields of hippocampus among phenotypic variants of AD and FTLD‐tau (2021) (0)
CSF Abeta and Tau associations with 3-D hippocampal radial distance mapped in 282 ADNI subjects (2009) (0)
Biomarker Based Diagnosis Of Very Mild Alzheimer'S Disease: A Multicenter Study (2009) (0)
High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration (2015) (0)
Targeted lipidomic-pathway–guided genetic association with Alzheimer's disease–relevant endophenotypes (2013) (0)
A novel antibody‐free mass spectrometry panel of CSF biomarkers for synaptic dysfunction (2021) (0)
Deep Clinical and Neuropathological Phenotyping of Pick’s Disease (S39.001) (2016) (0)
Positive PIB-PET Is Associated with High Post-Mortem Amyloid Burden in Dementia Patients (P06.033) (2013) (0)
CSF BIOMARKER CORRELATES OF ARTAG NEUROPATHOLOGY (2019) (0)
Microtubule-stabilizing drugs for abrogation and prevention of Alzheimer's disease (2012) (0)
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease (2020) (0)
Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer’s disease (2016) (0)
Influence of rare RELN variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer’s disease (2015) (0)
The Alzheimer’s metabolome: Identification of novel markers and treatment targets (2015) (0)
Brain changes in 676 ADNI subjects: summary of 10 studies using tensor based-morphometry and automated hippocampal mapping (2009) (0)
IC-P-104 Imaging biomarkers to monitor treatment effects for Alzheimer’s disease trials: The Alzheimer’s disease imaging initiative (2006) (0)
IS LEPTIN A CAUSE OF HIPPOCAMPAL FORMATION INSULIN RESISTANCE IN MCI AND AD? (2019) (0)
Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery (2021) (0)
Apolipoprotein E ɛ4–related effects on cognition are limited to the Alzheimer’s disease spectrum (2021) (0)
Lateralized ante mortem and post mortem pathology in a case of Lewy body disease with corticobasal syndrome (2022) (0)
First Multicenter Qualification of an Assay (INNO-BIA Plasma Aß Forms Assay) for Measurement of ß-amyloid Proteins as Part of US-ADNI Efforts for Biomarker Qualification (2010) (0)
Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment (2014) (0)
Multiplex plasma panels as screening tools in Alzheimer's disease. (2010) (0)
Predictors of cognitive impairment in primary age-related tauopathy: an autopsy study (2021) (0)
Assessing the Clinical Meaningfulness of the Alzheimer’s Disease Composite Score (ADCOMS) Tool (2022) (0)
Title : Phosphorylated neurofilament heavy chain : a biomarker of survival for C 9 ORF 72-associated amyotrophic lateral sclerosis (2017) (0)
O4-06-02 TDP-43 AND BETA-AMYLOID PRECURSOR PROTEIN PROCESSING PRODUCTS IN CEREBROSPINAL FLUID OF PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL LOBAR DEGENERATION (0)
BOOK REVIEWS The Neuropathology of Dementia, 2nd Edition (2005) (0)
Parkinson's disease dementia: at the crossroads of α-synuclein, tau and amyloid-β (2014) (0)
Comparing MRI and CSF biomarkers in Alzheimer's disease: Intergroup discrimination and predicting clinical change (2009) (0)
O4-06-01 α-Internexin is present in the hallmark lesions of neuronal intermediate filament inclusion disease (2004) (0)
Non-negative matrix factorization evaluation of patterns of brain Aβ deposition in Parkinson’s disease, Alzheimer’s disease and normal controls on [18F]florbetapir PET (2018) (0)
Pairwise gene-protein association analysis on cerebrospinal fluid proteomics in the ADNI-1 cohort (2012) (0)
Common neuropathological features underlie distinct clinical presentations in three siblings with hereditary diffuse leukoencephalopathy with spheroids caused by CSF1R p.Arg782His (2015) (0)
A framework for informing segmentation of in vivo MRI with information derived from ex vivo imaging: Application in the medial temporal lobe. (2016) (0)
Plasma protein associations with hippocampal atrophy across the cognitive spectrum from normal aging to Alzheimer's disease (2011) (0)
TDP-43 pathology: A central brain pathology in age-related cognitive decline (2013) (0)
CSF and blood plasma mass spectrometry measures of Aβ, tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimer’s disease (2021) (0)
PL-5-1 Molecular pathology/histopathology of AD (2004) (0)
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration (2020) (0)
Featured Article Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease (2016) (0)
Tau‐Neurodegeneration mismatch reveals vulnerability and resilience in Alzheimer’s continuum and Non‐Alzheimer’s pathophysiology (2022) (0)
CSF SMALL RNA BIOMARKERS FOR ALZHEIMER’S DISEASE (2018) (0)
EXPRESSION OF TRK-C RECEPTORS IN PRIMITIVE NEUROECTODERMAL TUMOR/ MEDULLOBLASTOMA CORRELATES WITH THE EXPRESSION OF NEUROFILAMENT PROTEINS AND IS ASSOCIATED WITH FAVORABLE PROGNOSIS (1999) (0)
1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
Quantitative digital image analysis of Pick’s disease neuropatholgy (P5.012) (2015) (0)
Progression of motor neuron disease is accelerated and the ability to recover is compromised with advanced age in rNLS8 mice (2016) (0)
CONTRIBUTION OF TAU, TDP-43, β-AMYLOID AND α-SYNUCLEIN TO MEDIAL TEMPORAL LOBE ATROPHY (2019) (0)
Characterizing the Alzheimer's disease prefrontal cortex transcriptome by multiple RNA-sequencing (2013) (0)
3-D mapping of associations amongst amyloid-PET and CSF biomarkers and hippocampal morphology (2009) (0)
Detection of Alzheimer’s Disease Pathology in patients usingbiochemical biomarkers: prospects and challenges for use in clinicalpractice (2020) (0)
3D mapping of associations amongst amyloid-PET and CSF biomarkers and hippocampal morphology (2009) (0)
Amyloid-β PET imaging of Alzheimer pathology in Parkinson disease dementia (P2.180) (2015) (0)
Alzheimer Research Forum Live Discussion : Alzheimer ’ s : A triple whammy . Why are so many neurodegenerative diseases single , double , or triple amyloidoses ? (2005) (0)
Synapsin-caveolin-1 Mitigates Cognitive Deficits and Neurodegeneration in PSAPP Mice (2020) (0)
P1-389 Increase of 12/15 lipooxygenase AD: potential role in oxidative stress (2004) (0)
Slow motor neurons resist pathological TDP-43 and mediate motor recovery in the rNLS8 model of amyotrophic lateral sclerosis (2022) (0)
ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer’s disease (2022) (0)
Vulnerability of the Neuronal Cytoskeleton in Aging and Alzheimer Disease: Widespread Involvement of All Three Major Filament Systems (1990) (0)
P2-098: Comparison of diagnostics values of cerebrospinal fluid tau and structural magnetic resonance imaging in classifying patients with Alzheimer's disease versus normal subjects (2008) (0)
Apolipoprotein A1 Levels Are Associated with APOA1 Promoter Variation and Influence Parkinson's Disease Risk (S17.004) (2014) (0)
Association Studies of Neuropathologically-Confirmed Cases and Controls Reveals that the PARK10 Locus is a Major Contributor to Sporadic Parkinson disease. (S7.005) (2015) (0)
Relationship between CSF and plasma proteomic data in the ADNI-1 cohort (2012) (0)
Overview of the synucleinopathies (2000) (0)
PREFRONTAL CORTEX TRANSCRIPTOME BY MULTIPLE RNA-SEQUENCING (2013) (0)
Genetic Variation Near the SNCA Gene Associates with Parkinson’s Disease Motor Endophenotype and Progression (I1.002) (2016) (0)
Neuron-Specific Chain Expression High-Molecular-Weight Clathrin (1990) (0)
CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE (2017) (0)
The effect of age and amyloid status on hippocampal atrophy rate in normal controls and people with mild cognitive impairment in the ADNI cohort (2013) (0)
P1-360 Dose dependent improvements of fast axonal transport and motor impairment in PRPT44 tau transgenic mice treated with a MT stabilizing drug (2004) (0)
Cerebrospinal fluid biochemical biomarkers of depressive symptoms in older adults (2012) (0)
Automatic analysis and validation of digitized speech markers in Lewy body spectrum diseases with Alzheimer’s disease co‐pathology (2021) (0)
THE MULTIDOMAIN IMPAIRMENT RATING (MIR) SCALE: INITIAL RELIABILITY DATA ON A MULTIDIMENSIONAL SCALE DESIGNED FOR FTLD SPECTRUM DISORDERS (2019) (0)
Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions (2021) (0)
ATN classifications in a mixed cohort of frontotemporal lobar degeneration (FTLD) and Alzheimer’s disease (AD) pathology using cerebrospinal fluid neurofilament light chain (NFL) (2020) (0)
CONTRIBUTION OF TAU, TDP-43, β-AMYLOID AND α-SYNUCLEIN TO MEDIAL TEMPORAL LOBE ATROPHY (2019) (0)
Supplemental Information Activation of HIPK 2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis (2016) (0)
Featured Articles Improved protocol for measurement of plasma b-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients (2012) (0)
THE ALZHEIMER’S METABOLOME: RELATIONSHIP TO PATHOLOGICAL MARKERS AND COGNITIVE DECLINE IN THE ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) (2016) (0)
THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER’S DISEASE PATHOLOGY (2018) (0)
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia (2018) (0)
Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice (2021) (0)
Influence of genetic variation on plasma proteomics in AD, MCI and controls: Pairwise gene-protein analysis in the ADNI-1 cohort (2011) (0)
Neuropathological and neuropsychological associations in hippocampal sclerosis of ageing; the 90+ study (P1.183) (2018) (0)
The Abeta Oligomer Selective Antibody Nab61 Recognizes Abeta Oligomers In The AD And APP Transgenic Mouse Brains And Neutralizes Abeta Mediated Synaptic Dysfunction (2009) (0)
Ultra-performance 2D-liquid chromatography–tandem mass spectrometry method for simultaneous analysis of beta-amyloid peptides: 1-38, 1-40 and 1-42 in human cerebrospinal fluid (2012) (0)
Improving Diagnostic Accuracy for Dementia: CSF Biomarker Cutoffs Based on Clinical and Neuropathological Criteria (IN3-1.010) (2012) (0)
Understanding Parkinson's Pathology is Key to Early Detection and Treatment (2014) (0)
Longitudinal Cognitive Performance and Cerebrospinal Fluid Biomarkers in Sporadic and Hereditary Frontotemporal Lobar Degeneration (P05.102) (2013) (0)
Ante Mortem Cerebrospinal Fluid Levels of Calsyntenin-1 and Neurexin-2a Reflect Post-Mortem TDP-43 Pathology in a Pathological Cohort of Frontotemporal Lobar Degeneration (2021) (0)
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau) (2019) (0)
STANDARDIZATION OF AMYLOID BETA 42 IN-HOUSE CALIBRATORS FOR A REFERENCE LC-MS-MS METHOD FOR ANALYSIS OF AMYLOID BETA 42 IN HUMAN CSF, USING THREE AVAILABLE CERTIFIED REFERENCE MATERIALS (2019) (0)
In Vivo T 1ρ -weighted MRI of Amyloid Transgenic Mouse Model of Alzheimer's Disease A B C (2003) (0)
Presence of Brain Amyloidosis Can Be Ascertained from Cognitive, Imaging and Peripheral Blood Protein Measures (IN3-1.004) (2013) (0)
O4-01-07 COMPREHENSIVE NEUROPSYCHOLOGICAL ASSESSMENT CAN DIFFERENTIATE BETWEEN ADULTSWITHMCIWHODEVELOPALZHEIMER’S DEMENTIA FROMTHOSEWHO RECOVER (2019) (0)
VALIDATING NON-AMYLOID, NON-TAU CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IN THE PRE-SYMPTOMATIC, MCI, AND DEMENTIA STAGES: A MULTI-CENTER STUDY (2017) (0)
Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals (2022) (0)
Retina tissue validation of optical coherence tomography determined outer nuclear layer loss in FTLD-tau (2021) (0)
A Unique Case of Cortical Myoclonus Sensitive to Visual Stimuli in the Peripersonal Space (2009) (0)
Author response. (2013) (0)
TYPE 2 DIABETIC RATS of IS LEPTIN A CAUSE OF HIPPOCAMPAL FORMATION INSULIN RESISTANCE IN MCI AND AD? IN REGULATING TAU PROTEIN PHOSPHORYLATION IN THE RETINA (2019) (0)
An integrated approach to the development of biomarkers for Alzheimer's disease using hospital population data (2012) (0)
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment (2010) (0)
The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer’s disease (2013) (0)
Improved Segmentation of Deep Sulci in Cortical Gray Matter Using a Deep Learning Framework Incorporating Laplace's Equation (2023) (0)
Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy (2016) (0)
Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy (2018) (0)
Preferential degeneration of the locus coeruleus in tauopathies relative to TDP‐43 proteinopathies (2020) (0)
Synuclein in Familial Alzheimer Disease (2016) (0)
Alpha-Synuclein aggregate formation in oligodendroglia OLN-t40 cells stably transfected with alpha-Synuclein (2007) (0)
Talbot-Wang - Brain Insulin Resistance in AD Suppl Data 4-2-12 (2013) (0)
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease (2018) (0)
Representative immunofluorescence histological findings of tauopathy model mice and wild type mice. (2011) (0)
Creating the Picks disease International Consortium: Association study of MAPT H2 haplotype with risk of Picks disease (2023) (0)
Advancing Alzheimer's Diagnosis, Treatment and Care: Recommendations from the Ware Invitational Summit (2013) (0)
Relationships of cerebrovascular atherosclerosis with amyloid, tau, α-synuclein and TDP-43 pathologies in neurodegenerative disease dementias (2012) (0)
ANALYTICAL AND CLINICAL PERFORMANCE OF AMYLOID BETA PEPTIDES: MEASUREMENT IN CSF OF ADNI2 AND GO PARTICIPANTS BY A LC-MS-MS REFERENCE METHOD (2018) (0)
Neuropathological subtypes among subjects with Alzheimer's disease (2012) (0)
A blood-based signature of cerebrospinal fluid Aβ1–42 status (2019) (0)
Genome-wide association analysis of Dementia with Lewy bodies reveals unique genetic architecture (2017) (0)
Brain changes in 676 ADNI subjects: Summary of 10 studies using tensor based morphometry and automated hippocampal mapping (2009) (0)
A NOVEL PATTERN OF TAU ISOFORMS IN FAMILIAL PICKʼS DISEASE (1999) (0)
Novel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins (2014) (0)
TDP-43 and beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration (2009) (0)
Title Common variant rs 356182 near SNCA defines a Parkinson ' s disease endophenotype (2016) (0)
ImpactoftheAlzheimer'sDiseaseNeuroimagingInitiative,2004to2014 (2015) (0)
Author response for "Distinct brain-derived TDP-43 strains from FTLD-TDP subtypes induce diverse morphological TDP-43 aggregates and spreading patterns in vitro and in vivo" (2021) (0)
Detection of astrocytic tau pathology facilitates recognition of chronic traumatic encephalopathy neuropathologic change (2022) (0)
SYNUCLEIN IMMUNOREACTIVITY IN OLFACTORY EPITHELIUM AS A BIOMARKER FOR NEURODEGENERATIVE DISEASE (1999) (0)
OP-JNEN200109 1141..1146 (2020) (0)
Subject Index Vol. 6, 2009 (2010) (0)
Utility of amyloid PET in the differential diagnosis of dementia: An autopsy-confirmed series (2013) (0)
Parkinson's Progression Markers Initiative brain autopsy program. (2022) (0)
BACE overexpression alters the subcellular processing of APP and inhibits A (cid:1) deposition in vivo (2005) (0)
Genome-wide association study of autopsy-confirmed Multiple System Atrophy identifies common variants near ZIC1 and ZIC4 (2021) (0)
AMNESTIC AND NON-AMNESTIC PHENOTYPES OF ALZHEIMER'S DISEASE: AN MRI-BASED PHASING ANALYSIS (2017) (0)
P4-004 Microdialysis reveals β-amyloid levels in brain interstitial fluid regulated by γ-secretase and neprilysin inhibitors as well as overexpression of β-secretase in vivo (2006) (0)
Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro (2021) (0)
Erratum (1979) (0)
P-057 Validation of the xMAP technology and performance of INNO-BIA AlzBio3 for quantification in CSF of Aβ1-42, total tau and P-tau181p (2007) (0)
Aging 6-2019 Limbic-Predominant Age-Related TDP-43 Encephalopathy ( LATE ) : Consensus Working Group Report (2019) (0)
CSF non-Beta-Amyloid, non-Tau Biomarkers for Clinical Alzheimer’s Disease Stages (S48.002) (2018) (0)
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies (2015) (0)
Astrocyte specific chromatin accessibility differences in European vs African Alzheimer Disease brains (2022) (0)
Application of histopathologically derived 3D tau burden map as in‐vivo region of interest for biomarker analysis (2021) (0)
COMPARING THE DIAGNOSTIC ACCURACIES OF CSF Aβ42 AND PET FLORBETAPIR (2014) (0)
CIRCULATING BRAIN-ENRICHED MICRORNAS AS BIOMARKERS FOR EARLY DETECTION AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE (2016) (0)
Phosphorylated Tau Is a Candidate Biomarker for Amyotrophic Lateral Sclerosis (P1.088) (2014) (0)
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (2020) (0)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
Clinical and Biochemical Differences between Parkinson's Disease Patients With and Without Mutations in the Glucocerebrosidase Gene (P06.072) (2012) (0)
Apolipoprotein E ε4 allele and schizophrenia (1997) (0)
Dysregulation of the epigenetic landscape of normal aging in Alzheimer’s disease (2018) (0)
TDP‐43 immunoreactivity in anoxic, ischemic and proliferating lesion of the central nervous system (2008) (0)
Intermediate Repeats Confer Risk for Corticobasal Degeneration and Increase C 9 orf 72 Expression (2020) (0)
Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy (2005) (0)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) (0)
P2-278 TRANSCALLOSAL CONDUCTION AND CENTRAL MOTOR CONDUCTION IN PEOPLE WITH A FAMILY HISTORY (2018) (0)
Synapsin-caveolin-1 mitigates cognitive deficits and neurodegeneration in Alzheimer’s disease mice (2020) (0)
Regional variations in brain atrophy, CSF biomarkers and ApoE relations (2010) (0)
Anxiety is related to Alzheimer's disease markers in cerebrospinal fluid of subjects with mild cognitive impairment (2011) (0)
Animal Models of Cerebral Ischemia: Neurodegeneration and Cell Transplantation (1998) (0)
Preclinical characterization and IND-enabling safety studies for PNT001, an antibody that recognizes cis-pT231 tau. (2023) (0)
A TOMM40 SNP IN APOE E4 NON-CARRIERS INCREASES RISK FOR MULTIPLE TYPES OF DEMENTIA (2013) (0)
Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of Aß, tau and P-tau versus 83 proteomic analytes (2012) (0)
Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease (2022) (0)
P3-052 Elevated CSF 8,12 isoprostane F2α-VL levels predict the presence of Alzheimer pathology (2004) (0)
Mechanisms of slow axonal transport of α-synuclein: 48.2 (2007) (0)
Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS (2017) (0)
Low serum levels of ApoE associate with hippocampal atrophy in the ADNI cohort (2011) (0)
Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies (2018) (0)
Human astrocytes exhibit an increased expression of the cellular senescence biomarker p16INK4a in aged human brain and Alzheimer's Disease (2011) (0)
Contents Vol. 6, 2009 (2010) (0)
Utility of amyloid PET in the differential diagnosis of dementia: An autopsy-confirmed series (2013) (0)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (0)
Subpial Thorn-shaped Astrocytes Are Prevalent In Guam ALS/PDC (2021) (0)
Distinct biological activity of Lewy body α-Synuclein strain in mice (2023) (0)
Identifying multi-analyte CSF biomarkers for Alzheimer’s disease in a multi-cohort study (2013) (0)
Characterization of Alterations in the Distribution of Amyloid Precursor Proteins and P-Amyloid Peptide after Experimental Brain Injury in the Rat (1996) (0)
Microglial activation precedes tau pathology and neurodegeneration in a P301S mutant tau transgenic mouse (2007) (0)
The Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol: Known Kindreds and Preliminary Data (P5.003) (2015) (0)
Peripheral blood plasma protein levels are associated with Pittsburgh compound B binding in the brain (2013) (0)
P2-207 Cortical biochemical markers of mild cognitive impairment (2006) (0)
Apolipoprotein E ɛ4–related effects on cognition are limited to the Alzheimer’s disease spectrum (2021) (0)
O2-06-04 Assessment of pathological tau proteins in new patients with R406W mutation in the tau gene (2004) (0)
PATHOLOGICAL DRIVERS OF NEURODEGENERATION IN SUSPECTED NON-ALZHEIMER’S PATHOPHYSIOLOGY (2019) (0)
Higher CSF STREM2/P‐tau ratio levels attenuate effects of polygenic Alzheimer’s disease risk on cognitive decline and neurodegeneration (2020) (0)
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration (2022) (0)
TMEM106B deficiency impairs cerebellar myelination and synaptic integrity with Purkinje cell loss (2022) (0)
P3-290 Enhanced tau pathology, cerebral atrophy and iron deposition induced by repetitive mild brain injury in a tau transgenic mouse (2006) (0)
Investigating key factors underlying neurodegeneration linked to alpha‐synuclein spread (2022) (0)
USING A BRAIN NETWORK APPROACH TO PREDICT GENETIC MUTATION IN INDIVIDUAL PATIENTS WITH FAMILIAL FRONTOTEMPORAL DEMENTIA (2018) (0)
Unfolding the medial temporal lobe to characterize neurodegeneration due to Alzheimer's disease pathology (2021) (0)
Regional analysis of abnormal tau protein distribution in progressive supranuclear palsy (2000) (0)
Regional Distribution of α-Synuclein and Alzheimer’s Disease pathology in Lewy Body Disorders (S45.002) (2018) (0)
INCREASED CSF SOLUBLE TREM2 IS ASSOCIATED WITH AMELIORATED LONGITUDINAL COGNITIVE AND CLINICAL DECLINE IN ALZHEIMER'S DISEASE (2019) (0)
Editorial Board (2007) (0)
AM-01 Introduction to the program (2007) (0)
Comparing MRI and CSF biomarkers in Alzheimer's disease: Intergroup discrimination and predicting clinical change (2009) (0)
Appendix: Dementia brain banks (2004) (0)
Automated deep learning segmentation of high-resolution 7 T ex vivo MRI for quantitative analysis of structure-pathology correlations in neurodegenerative diseases (2023) (0)
NEURODEGENERATION IN A TRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE (0)
Event-based modeling of T1-weighted MRI is related to pathology in frontotemporal lobar degeneration due to tau and TDP (2022) (0)
Mechanisms of slow axonal transport of {alpha}-synuclein (2007) (0)
Investigating the genetic architecture of Dementia with Lewy bodies: a genome-wide association study (2018) (0)
Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method. Running title: Amyloid beta in CSF of ADNIGO/2 participants (2020) (0)
Optimized extraction of the medial temporal lobe for postmortem MRI based on custom 3D printed molds (2020) (0)
Oral Sessions: O3-03: Biomarkers: Temporal Sequence of Biomarkers (2013) (0)
A CSF Signature of Frontotemporal Lobar Degeneration with C9orf72 Repeat Expansions (S18.003) (2014) (0)
Peripheral blood plasma protein levels are associated with Pittsburgh compound B-binding in the brain (2013) (0)
Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies. (2022) (0)
Original ArticleLoss of Dopamine D2 Receptors in Alzheimer’s Disease with Parkinsonism But Not Parkinson’s or Alzheimer’s Disease (1998) (0)
Comparison of Amyloid PET and CSF Biomarkers in the Evaluation of Dementia (PD1.004) (2012) (0)
brain-penetrant enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model. (2018) (0)
Alzheimer research forum live discussion: Making a BioMark on Alzheimer disease. (2005) (0)
The Penn ADCC: Integrating Neurodegenerative Disease Research Across Disciplines, Conditions, and Population Groups (2015) (0)
Establishing an Autopsy-Based Cerebrospinal Fluid Biomarker Signature in Alzheimer Disease Patients. (2022) (0)
Neuropathological Influences on the Clinical Phenotype of Synucleinopathies (P6.225) (2016) (0)
TAU CYTOPATHOLOGY IN A PATIENT WITH FAMILIAL EARLY ONSET DEMENTIA (1998) (0)
[18F]Florbetapir PET Imaging in Cognitively Normal Parkinson’s Disease (2015) (0)
The Schmitt symposium: The cytoskeleton and Alzheimer's disease an introduction (1995) (0)
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease (2022) (0)
Cognitive performance characteristics of individuals with normal or pathological CSF and MRI biomarkers of Alzheimer's disease (2009) (0)
P2-254 Imaging biomarkers to monitor treatment effects for Alzheimer’s disease trials: The Alzheimer’s disease imaging initiative (2006) (0)
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology (2019) (0)
CSF α-synuclein, BETA-AMYLOID 1-42 and tau proteins: Relationship to clinical parameters in early Parkinson's disease (2012) (0)
HERPES SIMPLEX VIRUS TYPE-1 (HSV-1) MUTANTS FOR THE TREATMENT OF CHILDHOOD BRAIN TUMORS (1996) (0)
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons (2018) (0)
P3-370 Long-term accumulations of amyloid-β in axons without prolonged amyloid plaque formation after brain trauma in humans (2004) (0)
Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus (2012) (0)
Relationships of cerebrovascular atherosclerosis with amyloid, tau, α-synuclein and TDP-43 pathologies in neurodegenerative disease dementias (2012) (0)
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies (2013) (0)
Degradative organelles containing mislocalized (cid:1) - and (cid:2) -synuclein proliferate in presenilin-1 null neurons (2004) (0)
O2-01-03 Impaired glutamate transport and excitotoxicity in a mouse model of tau pathology in astrocytes (2006) (0)
Biochemical Biomarkers of Depressive Symptoms in ADNI (2011) (0)
Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain (2018) (0)
Radioiodinated styrylbenzene derivatives as probes for imaging amyloid (2001) (0)
Brain Aβ amyloid measures and MRI are complimentary predictors of progression from MCI to Alzheimer's disease (2010) (0)
Learning from Our Mistakes: APOE4 Influences Misdiagnosis of Alzheimer’s Disease and Frontotemporal Degeneration (P5.208) (2014) (0)
Lewy bodies may influence symptomatology in some cases of presenilin-related Alzheimer's disease (2000) (0)
Developing Topics e65 P4-440 DECLINE IN TAU LEVELS FROM ANTISENSE OLIGO TREATMENT: A POTENTIAL CURATIVE MECHANISM FOR ALZHEIMER’S DISEASE (2011) (0)
The art and science of anti-aging therapies. (2005) (0)
Impact on management of new diagnostic tests in Alzheimer's disease (1996) (0)
Correction to: Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration (2023) (0)
Ftld-tdp to Tau Ratio Is a Biomarker for 181 Reduced Csf P-tau (0)
An Aptamer-Based Screen of 1000+ Plasma Proteins for Diagnostic Biomarkers in Parkinson's Disease (P4.047) (2014) (0)
INFLUENCE OF RARE PSEN1 VARIANTS ON QUANTITATIVE STRUCTURAL IMAGING AND CSF PHENOTYPES IN LATE ONSET ALZHEIMER'S DISEASE (2014) (0)
TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI (2019) (0)
The neuropathology of neurodegeneration with brain iron accumulation, type 1 (NBIA 1) contains insoluble α-synuclean (2000) (0)
Online Exclusive Cognitive and functional resilience despite molecular evidence of Alzheimer's disease pathology (2013) (0)
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation (2020) (0)
A candidate reference method for analysis of amyloid beta 1-42 (Aß1-42) peptide in human CSF using 2D-HPLC with a xevo t q-s mass spectrometer (2015) (0)
α-Synuclein nitration in neuropathological inclusions (2000) (0)
Erratum: CSF biomarker variability in the Alzheimer's Association quality control program (Alzheimer's and Dementia (2013) 9 (251-261)) (2015) (0)
Brief overview of the symposium (2002) (0)
Comparing predictors of conversion: Data from the Alzheimer's Disease Neuroimaging Initiative (2009) (0)
Lower neocortical tau burden distinguishes Alzheimer’s pathology occurring with vs. without primary non‐Alzheimer’s pathology (2020) (0)
Mapping tau burden and neuronal loss in MAPT‐associated frontotemporal lobar degeneration (2021) (0)
Clinical Markers of Frontal Tau Pathology in 4-Repeat Tauopathies (P6.241) (2016) (0)
253 Assembly of soluble β-amyloid peptides into Alzheimer disease amyloid fibrils in rat brain (1996) (0)
Reply (2005) (0)
Genetic Influences of Survival in the Behavioral Variant of Frontotemporal Degeneration (P4.014) (2014) (0)
Increased Cerebrospinal Fluid Total-Tau Levels in Hereditary Behavioral-Variant Frontotemporal Dementia (P5.030) (2015) (0)
Plasma multianalyte profiling of mild cognitive impairment and Alzheimer's disease in two academic centers and the Alzheimer's Disease Neuroimaging Initiative (2011) (0)
Qualification of a surrogate matrix-based absolute quantification method for beta-amyloid peptides in human CSF using 2D UPLC-SRM mass spectrometry (2013) (0)
CHARACTERISTICS AND PROGRESS OF 320 SUBJECTS IN THE LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) PROTOCOL (2018) (0)
The Role of Age and Genetic Markers on Cerebrospinal Fluid Tau Levels in Pathology-Confirmed Frontotemporal Degeneration (P1.219) (2015) (0)
Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo (2018) (0)
Survey of AMD and Normal Maculas for Amyloid-Beta Containing Vesicles (2003) (0)
Symposium 3: Function and Pathogenesis in Parkinson’s Disease (2008) (0)
Unfolding the Medial Temporal Lobe Cortex to Characterize Neurodegeneration Due to Alzheimer's Disease Pathology Using Ex vivo Imaging (2021) (0)
eScholarship Title Clinical and multimodal biomarker correlates of ADNI neuropathological findings Permalink (2013) (0)
ASSOCIATION OF OLFACTORY SCORE WITH LONGITUDINAL COGNITION AND NEUROPATHOLOGICAL DIAGNOSIS (2018) (0)
GFAP immunohistochemical assessment of astrocytosis in ventromedial temporal lobe limbic cortices in elderly patients with schizophrenia (1995) (0)
Featured Article The transitional association between b-amyloid pathology and regional brain atrophy (2015) (0)
Mechanisms of slow axonal transport of α‐synuclein (2007) (0)
SERUM TRIGLYCERIDES IN ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING, CSF, AND GENETIC VARIATION (2019) (0)
enzyme-linked immunosorbent NONLINEAR N-SCORE ESTIMATION FOR ESTABLISHING COGNITIVE NORMS FROM (2018) (0)
ASSOCIATION ANALYSIS OF RARE VARIANTS NEAR THE APOE REGION WITH CEREBROSPINAL FLUID (CSF) BIOMARKERS OF ALZHEIMER'S DISEASE (2014) (0)
Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization (2022) (0)
Plasma GFAP:NfL discriminates FTLD‐tau from FTLD‐TDP (2022) (0)
P3‐013: Withdrawn (2015) (0)
ALZHEIMER’S DISEASE AND THE HIPPOCAMPUS: NOVEL INSIGHTS FROM AN EX VIVO COMPUTATIONAL ATLAS COMBINING MRI AND HISTOLOGY (2017) (0)

This paper list is powered by the following services:

Other Resources About John Q. Trojanowski

en.wikipedia.org

What Schools Are Affiliated With John Q. Trojanowski?

John Q. Trojanowski is affiliated with the following schools:

John Q. Trojanowski's Academic­Influence.com Rankings

John Q. Trojanowski's Degrees

Why Is John Q. Trojanowski Influential?

John Q. Trojanowski's Published Works

Published Works

Other Resources About John Q. Trojanowski

What Schools Are Affiliated With John Q. Trojanowski?

John Q. Trojanowski's AcademicInfluence.com Rankings